



# Chicago





# Improvement Through Innovation

*Innovation, simply put, is trying something new. It's the heart of our work. Or maybe the soul. With each and every trial, we're testing a new treatment or prevention strategy, or trying to improve quality of life for survivors.*

Some trials really push that boundary, using new science or new designs or new classes of drugs. We've done all that in the last year, becoming the first group in the NCI's National Clinical Trials Network to activate a financial toxicity trial and the first immunotherapy trial for rare cancers.

This spring, we heard about our most innovative treatment trials. Here in Chicago, we'll hear about our most ground-breaking trials arising in our survivorship and prevention and epidemiology committees.



Innovation is not only our group meeting theme for 2017. It's also something we've been living all year long here at SWOG. In January, we submit our next five-year NCTN grant request. It's a recounting of what we've achieved since 2014, and what we plan to achieve through 2024. At this meeting, I'll meet with my leadership team for the last time, in person, to review our grant strategy and writing progress.

Planning for the future is exciting, and I've never felt better about where SWOG is, and where we are headed. Palliative care, immunotherapy, diversity, digital engagement – our new directions are going to lead us to good destinations. For our members – and most importantly, our patients.

As always, thanks for your commitment to SWOG and our clinical trials. Enjoy the meeting here in Chicago.

*Charles Blum*



*“I’m privileged to provide the patient perspective on our SWOG Myeloma Committee and appreciate Hope’s critical support.”*

# Helping SWOG Do More

*SWOG formally invited patient advocates into its research activities in 1993, the same year The Hope Foundation was established.*

*Since that time, Hope has continually funded travel and professional development to further advocates’ important work.*

*Text “SWOG” to 41444 to give today.*

**25 Years of  
Supporting SWOG**

*Jack Aiello, MS, EE  
SWOG Patient Advocate,  
Myeloma Committee*

## THE HOPE FOUNDATION

*Because answers to cancers come from clinical trials*



# Group Meeting Index

Plenary Sessions .....	6, 17 & 19
The Hope Foundation .....	4 & 21
CME Credit Information.....	8 & 9
Group Meeting Supporters .....	9 & 71
Hyatt Regency Travel and Hotel Information and Hotel Maps .....	12-15
Schedule of Events.....	16-19
Committee Information:	
Adolescent and Young Adult (AYA) Committee .....	17
Barlogie-Salmon Myeloma Committee .....	18 & 23-24
Breast Committee .....	19 & 25-29
Board of Governors.....	19
Bone Marrow & Stem Cell Transplantation Committee.....	18
Cancer Care Delivery Committee .....	17 & 32-33
Cancer Survivorship Committee.....	17 & 34
Committee Chairs .....	19
Digital Engagement Committee.....	17
Early Therapeutics & Rare Cancers Committee.....	17 & 40-41
Gastrointestinal Committee .....	19 & 42-45
Genitourinary Committee .....	19 & 46-49
Imaging Committee.....	18
Leukemia Committee .....	19 & 50-53
Lung Committee .....	17 & 54-57
Lymphoma Committee.....	19 & 58-59
Melanoma Committee .....	18 & 60-63
Patient Advocate Committee .....	16 & 17
Pharmaceutical Sciences Committee .....	19
Prevention & Epidemiology Committee .....	17 & 35-36
Publications Committee .....	18
Radiation Oncology Committee .....	19
Surgery Committee .....	7 & 18
Symptom Control & Quality of Life Committee .....	18 & 37-39
Jeri and Noboru Oishi Symposium .....	16
Oncology Research Professionals (ORP) Open Forum .....	17
Administrative and Research Committees .....	22
Future Group Meeting Dates.....	22
Special Symposia & Events.....	20-21
SWOG Publications .....	64-70



## Plenary Part I

The fall meeting's translational medicine plenary will take place Thursday, October 12, 3:00-4:30 p.m., in Regency A-C. Speakers and topics include the following:

### Welcome and Introduction



**Lee M. Ellis, MD**

*SWOG Vice Chair for  
Translational Medicine  
University of Texas  
M.D. Anderson Cancer Center*

### Harnessing the Power of Genomics in Correlative Studies



**Elaine R. Mardis, PhD**

*Nationwide Foundation  
Endowed Chair in Genomic  
Medicine  
Co-Executive Director, Institute  
for Genomic Medicine at  
Nationwide Children's Hospital  
Professor of Pediatrics  
The Ohio State University  
College of Medicine*

### Liquid Biopsies...What's Next?



**Luis Diaz, Jr., MD**

*Head, Division of Solid Tumor  
Oncology  
Department of Medicine  
Memorial Sloan Kettering  
Cancer Center*

### Understanding the Secrets of the SWOG Tissue Bank



**Nilsa C. Ramirez, MD, FCAP**

*Contact Principal Investigator,  
SWOG Biospecimen Bank  
Professor of Clinical Pathology  
The Ohio State University College  
of Medicine  
Nationwide Children's Hospital*

## Plenary Part II

The fall meeting's general plenary will take place Friday, October 13, 12:00-2:00 p.m., in Regency A-C.

### Chair's Welcome and Update



**Charles D. Blanke, MD**

*SWOG Chair  
Oregon Health & Science  
University*

### Innovation in SWOG NCORP Trials



**Katherine D. Crew, MD, MS**

*Associate Professor of Medicine  
and Epidemiology  
Division of Hematology/  
Oncology  
Director, Clinical Breast Cancer  
Prevention Program  
Herbert Irving Comprehensive  
Cancer Center  
Columbia University  
Medical Center*

### The Growing Landscape of Palliative Care

#### Dr. Harry E. Hynes Memorial Lecture



**Jeannine M. Brant, PhD, APRN, AOCN, FAAN**

*Oncology Clinical Nurse  
Specialist  
Nurse Scientist  
Pain Consultant  
Billings Clinic  
Cancer Care Delivery Lead  
Montana Cancer Consortium*

### Innovation in Cancer Clinical Trials:

#### How Are Trials Improved If Everyone Is Involved in the Medical Research Process?



**Larry Chu, MD**

*Executive Director  
Stanford Medicine X  
Professor  
Stanford University*



**Alicia C. Staley, MBA**

*Director of Patient Engagement  
Science 37  
Co-Founder  
Breast Cancer Social Media*



# SWOG Surgical Protocols

## Educational Session: Surgery Committee

OCTOBER 13, 2017  
9:00 – 11:00 A.M.

### **SI316: Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction**

**Virginia Sun, PhD, RN**

*Assistant Professor, Division of Nursing Research and Education  
Department of Population Sciences & Cancer Control and  
Population Sciences Program  
City of Hope*

### **A Personalized Dietary Intervention for Bowel Dysfunction in Rectal Cancer Survivors**

**Virginia Sun, PhD, RN**

### **Update on S1011: comparing extended vs. standard lymphadenectomy with radical Cystectomy for invasive Bladder cancer**

**Seth Paul Lerner, MD**

*Professor, Department of Urology  
Baylor College of Medicine*

### **Update: S0820: A Double Blind Randomized Placebo-Controlled Trial of DFMO and Sulindac to Prevent Recurrence of Adenomas in Patients with Stages I-III Colon and Rectal Cancer, Phase III**

**Jason A. Zell, DO, MPH**

*Associate Professor, Division of Hematology/Oncology,  
Departments of Medicine & Epidemiology  
University of California, Irvine*

### **E S1600 SIMmune: A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes**

**Jill Hamilton-Reeves, PhD, RD, CSO**

*Associate Professor  
Department of Urology and Dietetics/Nutrition  
University of Kansas Medical Center*

### **Trial Evaluating the Oncologic Safety of Laparoscopic versus Open Liver Resection**

**Claudius Conrad, MD**

*Department of Surgical Oncology, MD Anderson Cancer Center*

### **Hyperthermic Intraperitoneal Chemotherapy and Systemic Chemotherapy versus Systemic Chemotherapy Alone for High Volume Peritoneal Carcinomatosis of Colorectal Origin**

**Jig Deneve, DO FACS**

*Assistant Professor of Surgery  
UTHSC, Memphis, TN*

# New Procedures for CME Credit

***We've gone paperless! SWOG no longer requires members to submit paper forms to obtain CME credits. Getting your credits online is easy:***


- Visit: <http://swog.org/Members/CMECertification.asp>
- Complete the evaluation questions
- Enter the credits being claimed
- Press "submit"

*Your certificate will automatically be emailed to you.*

*Problems or questions? Contact Courtney Wille in the SWOG operations office at [cwille@swog.org](mailto:cwille@swog.org).*

*To keep track of your credits during the meeting, use the form on the next page.*

Time	Session Title	Available Credit	Actual Credit
THURSDAY, OCTOBER 12, 2017			
8:00 a.m. – 10:00 a.m.	Cancer Survivorship Committee	2.0	_____
10:00 a.m. – 12:15 p.m.	Early Therapeutics & Rare Cancers Committee	2.25	_____
10:15 a.m. – 12:15 p.m.	Cancer Care Delivery Committee	2.0	_____
12:30 p.m. – 2:30 p.m.	Prevention and Epidemiology Committee	2.0	_____
3:00 p.m. – 4:30 p.m.	Plenary I (Translational Medicine)	1.5	_____
4:45 p.m. – 7:45 p.m.	Lung Committee	3.0	_____
FRIDAY, OCTOBER 13, 2017			
7:30 a.m. – 9:30 a.m.	Barlogie-Salmon Myeloma Committee	2.0	_____
7:30 a.m. – 9:30 a.m.	Symptom Control and Quality of Life Committee	2.0	_____
9:00 a.m. – 11:00 a.m.	Surgery Committee	2.0	_____
9:30 a.m. – 11:30 a.m.	Melanoma Committee	2.0	_____
12:00 p.m. – 2:00 p.m.	Plenary II (General)	2.0	_____
4:00 p.m. – 7:00 p.m.	Lymphoma Committee	3.0	_____
4:30 p.m. – 6:30 p.m.	GI Committee	2.0	_____
SATURDAY, OCTOBER 14, 2017			
9:30 a.m. – 11:30 a.m.	Radiation Oncology Committee	2.0	_____
9:30 a.m. – 11:30 a.m.	Leukemia Committee	2.0	_____
9:30 a.m. – 12:30 p.m.	GU Committee	3.0	_____
9:30 a.m. – 12:30 p.m.	Breast Committee	3.0	_____
<b>Total Possible Credits</b>		<b>22.75</b>	_____





# Procedures for CME Credit

## Group Meeting Target Audience and Educational Objectives

SWOG meets semi-annually to keep its members abreast of group science. The target audience for these meetings are physicians, nurse oncologists and clinical research associates.

The educational objectives of these meetings are: to educate attendees about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments and prevention strategies that are available; to identify areas that can be improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.

These objectives apply to the following areas: Cancer Control and Prevention, including Cancer Care Delivery Committee, Symptom Control and Quality of Life Committee, Prevention & Epidemiology Committee, Cancer Survivorship Committee; Genitourinary Committee; Early Therapeutics & Rare Cancers Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; Radiation Oncology Committee; Plenary Sessions Part I and II; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee, and Lymphoma Committee.

## Continuing Medical Education Credit

The Hope Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Hope Foundation designates this live activity for a maximum of 22.75 **AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## Speaker and Planner CME Disclosure Information

Each speaker and planner for The Hope Foundation — CME courses has been requested to complete a Faculty Disclosure Form prior to the activity in accordance with ACCME standards. THF strives to provide accurate and up-to-date information regarding affiliations or interests that might be perceived as a potential conflict of interest for those who control CME content. Please see the disclosure handout available at the SWOG self-service and onsite registration desks. Best attempts will also be made to provide up to date information on introductory slides at each CME session.

SWOG gratefully acknowledges the support of our CME Commercial Supporters\*



PLATINUM

Celgene  
Eli Lilly & Co.



GOLD

AbbVie  
Novartis



SILVER

AstraZeneca  
Genomic Health  
Merck

\* Supporters as of Sept. 18, 2017

**We've gone paperless! SWOG no longer requires members to submit paper forms to obtain CME credits. Getting your credits online is easy:**

- Visit: <http://swog.org/Members/CMECertification.asp>
- Complete the evaluation questions
- Enter the credits being claimed
- Press "submit"

Your certificate will automatically be emailed to you.

Problems or questions? Contact Courtney Wille in the SWOG operations office at [cwille@swog.org](mailto:cwille@swog.org).

To keep track of your credits during the meeting, use the form below.

# We're now on Facebook

We've launched a private Facebook group — **SWOG Oncology** — to create an online meeting place for every **SWOG** member.

Join the group and you'll get news from **SWOG** and funding alerts from **The Hope Foundation**. You can also talk clinical trial triumphs and troubleshooting, picking up best practices and getting advice on study challenges.

It's easy to sign up.

Log onto Facebook, search for "**SWOG Oncology**" and hit the green "**Join Group**" button. You'll get a notification when your access is approved.

**SWOG**  Leading cancer research. **Together.**



Public Powered Cancer Research




## Tweet the meeting

Tag your group meeting tweets with  
**#swogonc**

We'll post the live stream of tagged group meeting updates to the SWOG website, for ease of following by those who couldn't make it.

Follow SWOG at [twitter.com/SWOG](https://twitter.com/SWOG).

Our username is **@SWOG**.





# We're launching a new website!

By the end of the year, the new SWOG.org will go live – our first major website redesign. The entire site has been redesigned, rewritten, and rebuilt based on member feedback.

Improvements include:


- One-step login
- Easier navigation
- Improved member directory
- Improved trial and publications search tool
- Handy member resource page
- Member stories
- Patient testimonials
- New videos

Visit SWOG.org to learn more about getting new login credentials through CTEP or SWOG.

We want you to access all the new online tools, news, and information!


- SWOG statistics updated daily
- Easy single-step login
- Improved search tools
- News and announcements

- Special member resources
- Better connection to The Hope Foundation



# Chicago Travel & Hotel Information

**Hyatt Regency Chicago 151 East Wacker Drive Chicago, Illinois 60601 • Phone: 312-565-1234 • Fax: 312 239 4541**



## **Arrival/Departure:**

Check-in time is 3:00 p.m. Check-out time is 12:00 noon. Room amenities include a full bath, hair dryer, ironing board and iron. The concierge staff serves as a liaison between guests and the hotel and outside services.

## **Hotel Safety Deposit Boxes:**

For your convenience, safety deposit boxes are available at the front desk for your valuables. Please do not leave valuables in your room.

## **Recreational Facilities:**

The fitness center offers a variety of exercise equipment, free weights, treadmills, and more, exclusively for hotel guests. *It is open 24 hours a day.*

**Hotel Restaurants and Lounges:** Stetsons Modern Steak & Sushi: Non-traditional steakhouse experience in a comfortable urban setting, specializing in steaks and seafood. *Restaurant is open daily from 5:00 p.m. - 11:00 p.m.*

**American Craft Kitchen & Bar:** Regionally inspired by all corners of the country, they offer an approachable dining experience with handcrafted food and drink. This atrium restaurant is the perfect stop for breakfast or lunch. *Open daily from 6:00 a.m. - 3:00 p.m.*

**Market Chicago:** Offers breakfast, lunch or dinner for a quick meal or coffee to go. *Open 24 hours a day.*

**DaddyO's Pub & Game Room:** Corner pub featuring juicy burgers, local brews and wall-to-wall entertainment. *Open 5:00 p.m. - 1:00 a.m.*

**The BIG Bar** features the longest free-standing bar in North America and specializes in a wide variety of cocktails, wines, champagnes and cognacs and snacks. *Open daily at 5:00 p.m.*

*In-room dining is available from 6:00 a.m. - 12:00 a.m. daily.*

## **Business Center:**

The Business Center is located on the Purple level in the East Tower of the hotel. It is open 24 hours a day, 7 days a week. The Business Center offers fax machines, computer services, color copies, mail drop, Internet access and photocopying.



# Chicago Travel & Hotel Information, cont.

## Ground Transportation:

A taxi ride from O'Hare International Airport to the hotel is approximately \$35.00 one-way.

A taxi ride from Midway International Airport to the hotel is approximately \$30.00 one-way.

Valet parking at the hotel is a maximum of \$65.00 per day for hotel guests.

## Temperature:

The average high for September is 75 degrees and the average low is 54 degrees.

## AREA ATTRACTIONS:

- Adler Planetarium and Astronomy Museum
- Architectural Boat Tours
- Art Institute of Chicago
- Brookfield Zoo
- Chicago ArchiCenter
- Chicago Architecture Foundation
- Chicago Botanic Garden
- Field Museum of Natural History
- John G. Shedd Aquarium
- John Hancock Center Observatory
- Millennium Park
- Museum of Contemporary Art
- Museum of Science and Industry
- Rockefeller Memorial Chapel
- Sears Tower Skydeck

## Local Restaurants:

*(The hotel concierge can assist with reservations and suggestions)*

- Alinea - *Eclectic*
- Atwood Cafe - *American*
- Mia Francesca - *Italian*
- Mon Ami Gabi - *French*
- Shaw's Crab House and Blue Crab Lounge - *Seafood*
- Spiaggia - *Italian*





## WELCOME TO HYATT REGENCY CHICAGO.



Meeting rooms, ballrooms, restaurants and guest amenities are listed in alphabetical order and color coded by floor. For help, dial Guest Services at Extension **4460**.

ACAPULCO ( <i>International and City Suites</i> ) West Tower, Ballroom Level	HONG KONG ( <i>International and City Suites</i> ) West Tower, Ballroom Level
ADDAMS ( <i>Founders Suites</i> ) West Tower, Third Floor	HORNER ( <i>Founders Suites</i> ) West Tower, Third Floor
AMERICAN CRAFT KITCHEN & BAR East Tower, Lobby Level	THE LIVING ROOM West Tower, Skyway Level
ATLANTA ( <i>International and City Suites</i> ) West Tower, Ballroom Level	MARKET CHICAGO East Tower, Lobby Level
BELL DESK East Tower, Skyway Level	MCCORMICK ( <i>Founders Suites</i> ) West Tower, Third Floor
BIG BAR East Tower, Skyway Level	MICHIGAN ( <i>Lakeshore Meeting Rooms</i> ) East Tower, Concourse Level
BURNHAM ( <i>Founders Suites</i> ) West Tower, Third Floor	MONROE ( <i>Lakeshore Meeting Rooms</i> ) East Tower, Concourse Level
BUSINESS CENTER, PACKAGE ROOM East Tower, Exhibit Level	NEW ORLEANS ( <i>International and City Suites</i> ) West Tower, Ballroom Level
COLUMBIAN ( <i>Landmark Suites</i> ) West Tower, Concourse Level	OGDEN ( <i>Founders Suites</i> ) West Tower, Third Floor
COLUMBUS HALL (ROOMS A-L) East Tower, Ballroom Level	PICASSO ( <i>Landmark Suites</i> ) West Tower, Concourse Level
COMISKEY ( <i>Landmark Suites</i> ) West Tower, Concourse Level	PLAZA BALLROOM East Tower, Lobby Level
CONCIERGE East Tower, Lobby Level	RANDOLPH ( <i>Lakeshore Meeting Rooms</i> ) East Tower, Concourse Level
CRYSTAL BALLROOM West Tower, Lobby Level	REGENCY BALLROOM West Tower, Ballroom Level
DUSABLE ( <i>Founders Suites</i> ) West Tower, Third Floor	RIVERSIDE CENTER East Tower, Exhibit Level
EAST TOWER MAIN ENTRANCE East Tower, Lobby Level	ROOSEVELT ( <i>Lakeshore Meeting Rooms</i> ) East Tower, Concourse Level
EAST TOWER VALET East Tower, Ballroom Level	SAN FRANCISCO ( <i>International and City Suites</i> ) West Tower, Ballroom Level
FIELD ( <i>Founders Suites</i> ) West Tower, Third Floor	SANDBURG ( <i>Founders Suites</i> ) West Tower, Third Floor
FITNESS CENTER West Tower, Skyway Level	SKYWAY MEETING ROOMS East Tower, Skyway Level
FRONT DESK East Tower, Skyway Level	SOLDIER FIELD ( <i>Landmark Suites</i> ) West Tower, Concourse Level
THE GALLERY COLLECTION West Tower, Skyway Level	STETSON CONFERENCE CENTER West Tower, Exhibit Level
GIFT SHOP East Tower, Concourse Level	STETSONS MODERN STEAK + SUSHI East Tower, Lobby Level
GOLD COAST ( <i>Landmark Suites</i> ) West Tower, Concourse Level	TORONTO ( <i>International and City Suites</i> ) West Tower, Ballroom Level
GRAND BALLROOM East Tower, Ballroom Level	WATER TOWER ( <i>Landmark Suites</i> ) West Tower, Concourse Level
GRAND SUITES East Tower, Ballroom Level	WEST TOWER VALET West Tower, Exhibit Level
HAYMARKET ( <i>Landmark Suites</i> ) West Tower, Concourse Level	WRIGHT ( <i>Founders Suites</i> ) West Tower, Third Floor
HERTZ East Tower, Lobby Level	WRIGLEY ( <i>Landmark Suites</i> ) West Tower, Concourse Level







## EAST TOWER

## WEST TOWER

**SKYWAY LEVEL**  
Blue Level**LOBBY LEVEL**  
Green Level

WACKER DRIVE

**CONCOURSE LEVEL**  
Bronze Level**BALLROOM LEVEL**  
Gold Level**RIVERSIDE EXHIBIT LEVEL**  
Purple Level

-  ELEVATORS
-  ESCALATORS AND STAIRS
-  RESTROOMS
-  MOTHER'S ROOM

**ESCALATORS, ELEVATORS AND RESTROOMS** are indicated on each floor. Elevators are conveniently located throughout the hotel for guests with disabilities or where no escalator is present.

**CROSSING BETWEEN TOWERS:** Cross between towers via the Skybridge or the Concourse. You may also cross from the lobby level via the crosswalk on Stetson Drive.

# Schedule of Events

Order of Levels (top to bottom): **Skyway Level** | **Lobby Level** | **Concourse Level** | **Ballroom Level** | **Riverside Exhibit Level**

## Wednesday, October 11, 2017

### Group Meeting Registration & Information Desk

**1:00 p.m. - 5:00 p.m. - Regency Foyer,  
Ballroom Level, West Tower**

8:00 A.M. - 12:00 P.M.

Wrigley, Concourse Level, West Tower

**Grant Retreat  
(Executive Leadership/  
Invitation Only)**

10:00 A.M. - 12:00 P.M.

Soldier Field, Concourse Level, West Tower

**ORP Executive  
Committee (Committee  
Members Only)**

12:00 P.M. - 1:45 P.M.

Haymarket, Concourse Level, West Tower

**Nursing Research  
Subcommittee**

12:00 P.M. - 2:00 P.M.

Water Tower, Concourse Level, West Tower

**Core Office Staff  
Meeting (Invitation  
Only)**

1:00 P.M. - 5:00 P.M.

Gold Coast, Concourse Level, West Tower

**SoCRA Certification  
Examination**

1:00 P.M. - 5:00 P.M.

Regency B, Ballroom Level, West Tower

**SWOG NCORP Research  
Base Clinical Trials  
Workshop**

2:00 P.M. - 3:30 P.M.

Soldier Field, Concourse Level, West Tower

**SWOG Tissue Banking  
Meeting (Invitation  
Only)**

3:00 P.M. - 4:30 P.M.

Water Tower, Concourse Level, West Tower

**Task Force on Palliative  
Medicine and Advance  
Care Planning**

3:30 P.M. - 5:30 P.M.

Wrigley, Concourse Level, West Tower

**Hope Foundation  
Board Meeting (Board  
Members Only)**

4:30 P.M. - 5:30 P.M.

Comiskey, Concourse Level, West Tower

**ORP Liaison  
Subcommittee**

5:30 P.M. - 7:30 P.M.

Acapulco, Ballroom Level, West Tower

**Site Operations  
(Formerly Head  
CRA - Open Session)**

5:30 P.M. - 8:00 P.M.

Regency C, Ballroom Level, West Tower

**NCORP Research Base  
Executive Committee  
Meeting (Committee  
Members Only)**

6:30 P.M. - 8:30 P.M.

Haymarket, Concourse Level, West Tower

**ITSC Steering  
Committee (Committee  
Members Only)**

## Thursday, October 12, 2017

### Group Meeting Registration & Information Desk

**7:00 a.m. - 5:00 p.m. - Regency Foyer,  
Ballroom Level, West Tower**

### Hope Foundation Information Desk

**8:00 a.m. - 5:00 p.m. - Regency Foyer,  
Ballroom Level, West Tower**

### Exhibits & Complimentary Coffee Service

**7:00 a.m. - 4:00 p.m. - Toronto/Hong Kong,  
Ballroom Level, West Tower**

7:00 A.M. - 8:00 A.M.

New Orleans, Ballroom Level, West Tower

**Advocates Committee  
Meeting (Committee  
Members Only)**

7:30 A.M. - 8:00 A.M.

Regency B, Ballroom Level, West Tower

**Jeri & Noboru Oishi  
Symposium Check-In**

8:00 A.M. - 12:00 P.M.

Regency AB, Ballroom Level, West Tower

**Jeri & Noboru Oishi  
Symposium (Open  
Session)**

8:00 A.M. - 9:00 A.M.

Haymarket, Concourse Level, West Tower

**Professional Review  
Committee (Committee  
Members Only)**



# Schedule of Events

Order of Levels (top to bottom): **Skyway Level** | **Lobby Level** | **Concourse Level** | **Ballroom Level** | **Riverside Exhibit Level**

## 8:00 A.M. – 10:00 A.M.

Regency D, Ballroom Level, West Tower

**CANCER SURVIVORSHIP  
COMMITTEE**

## 8:00 A.M. – 10:00 A.M.

San Francisco, Ballroom Level, West Tower

**Lung-MAP Site  
Coordinators  
Committee Meeting  
(Committee Members  
Only)**

## 9:00 A.M. – 10:00 A.M.

Soldier Field, Concourse Level, West Tower

**Lung Surgery  
Subcommittee  
(Committee Members  
Only)**

## 9:00 A.M. – 10:00 A.M.

Regency C, Ballroom Level, West Tower

**S1609 DART Protocol  
Meeting**

## 10:00 A.M. – 12:00 P.M.

Water Tower, Concourse Level, West Tower

**Digital Engagement  
Committee (Committee  
Members Only)**

## 10:00 A.M. – 12:00 P.M.

Haymarket, Concourse Level, West Tower

**Quality Initiative  
Meeting (Committee  
Members Only)**

## 10:00 A.M. – 12:15 P.M.

Regency C, Ballroom Level, West Tower

**EARLY THERAPEUTICS  
AND RARE CANCERS  
COMMITTEE**

## 10:15 A.M. – 12:15 P.M.

Regency D, Ballroom Level, West Tower

**CANCER CARE  
DELIVERY COMMITTEE**

## 10:30 A.M. – 11:30 A.M.

Soldier Field, Concourse Level, West Tower

**Lung Radiation  
Subcommittee  
(Committee Members  
Only)**

## 12:00 P.M. – 2:00 P.M.

Comiskey, Concourse Level, West Tower

**Adolescent and Young  
Adult (AYA) Committee**

## 12:30 P.M. – 2:00 P.M.

Acapulco, Ballroom Level, West Tower

**ORP Open Forum**

## 12:30 P.M. – 2:30 P.M.

Regency D, Ballroom Level, West Tower

**PREVENTION AND  
EPIDEMIOLOGY  
COMMITTEE**

## 12:30 P.M. – 2:30 P.M.

Water Tower, Concourse Level, West Tower

**Lung Working Group  
(Working Group  
Members Only)**

## 1:00 P.M. – 3:00 P.M.

New Orleans, Ballroom Level, West Tower

**Lymphoma Working  
Group Meeting  
(Working  
Group Members Only)**

## 2:00 P.M. – 3:00 P.M.

Regency Foyer, Ballroom Level, West Tower

**Plenary Reception**

## 2:00 P.M. – 3:00 P.M.

Soldier Field, Concourse Level, West Tower

**ORP Education  
Subcommittee**

## 3:00 P.M. – 4:30 P.M.

Regency A-C, Ballroom Level, West Tower

**PLENARY I  
(TRANSLATIONAL  
MEDICINE)**

## 3:00 P.M. – 4:30 P.M.

San Francisco, Ballroom Level, West Tower

**Advocates Committee  
Meeting (Committee  
Members Only)**

## 4:45 P.M. – 6:45 P.M.

Water Tower, Concourse Level, West Tower

**Breast Translational  
Medicine Working  
Group (Working Group  
Members Only)**

## 4:30 P.M. – 7:30 P.M.

Comiskey, Concourse Level, West Tower

**Myeloma Working  
Group Meeting  
(Working  
Group Members Only)**

## 4:45 P.M. – 7:45 P.M.

Regency D, Ballroom Level, West Tower

**LUNG COMMITTEE**

## 5:00 P.M. – 6:30 P.M.

New Orleans, Ballroom Level, West Tower

**Eagle II Reception  
(Invitation Only)**

# Schedule of Events

Order of Levels (top to bottom): **Skyway Level** | **Lobby Level** | **Concourse Level** | **Ballroom Level** | **Riverside Exhibit Level**

## 5:00 P.M. – 7:00 P.M.

Acapulco, Ballroom Level, West Tower

**Seminar: Developing Cultural Competence in Clinical Trials Research**

## 5:00 P.M. – 7:00 P.M.

Haymarket, Concourse Level, West Tower

**Conflict Management Committee (Committee Members Only)**

## 5:30 P.M. – 6:30 P.M.

Gold Coast, Concourse Level, West Tower

**S1316 Protocol Meeting**

## 7:00 P.M. – 9:00 P.M.

Gold Coast, Concourse Level, West Tower

**Latin American Symposium (Invitation Only)**

## Friday, October 13, 2017

**Group Meeting Registration & Information Desk**

**7:00 a.m. - 5:00 p.m. - Regency Foyer, Ballroom Level, West Tower**

**Hope Foundation Information Desk**

**8:00 a.m. - 5:00 p.m. - Regency Foyer, Ballroom Level, West Tower**

**Exhibits & Complimentary Coffee Service**

**7:00 a.m. - 4:00 p.m. - Toronto/Hong Kong, Ballroom Level, West Tower**

## 7:30 A.M. – 9:30 A.M.

Comiskey, Concourse Level, West Tower

**Melanoma Working Group Meeting (Working Group Members Only)**

## 7:30 A.M. – 9:30 A.M.

Crystal A, Lobby Level, West Tower

**BARLOGIE-SALMON MYELOMA COMMITTEE**

## 7:30 A.M. – 9:30 A.M.

New Orleans, Ballroom Level, West Tower

**Imaging Committee (Committee Members Only)**

## 7:30 A.M. – 9:30 A.M.

Regency D, Ballroom Level, West Tower

**SYMPTOM CONTROL AND QUALITY OF LIFE COMMITTEE**

## 7:30 A.M. – 9:30 A.M.

San Francisco, Ballroom Level, West Tower

**SWOG Data and Safety Monitoring Committee (Committee Members Only)**

## 9:00 A.M. – 10:00 A.M.

Crystal C, Lobby Level, West Tower

**S1602 and S1605 Joint Protocol Meeting**

## 9:00 A.M. – 11:00 A.M.

Acapulco, Ballroom Level, West Tower

**SURGERY COMMITTEE**

## 9:30 A.M. – 11:30 A.M.

Crystal B, Lobby Level, West Tower

**MELANOMA COMMITTEE**

## 9:30 A.M. – 11:30 A.M.

Randolph 3, Concourse Level, East Tower

**Leadership Academy (Invitation Only)**

## 10:00 A.M. – 11:30 A.M.

Haymarket, Concourse Level, West Tower

**Quality Assurance Committee Meeting (Committee Members Only)**

## 10:00 A.M. – 12:00 P.M.

Crystal A, Lobby Level, West Tower

**Breast Working Group Meeting (Working Group Members Only)**

## 10:30 A.M. – 12:00 P.M.

Gold Coast, Concourse Level, West Tower

**Bone Marrow & Stem Cell Transplantation Committee**

## 11:00 A.M. – 12:00 P.M.

San Francisco, Ballroom Level, West Tower

**Publications Committee (Committee Members Only)**

## 11:00 A.M. – 12:00 P.M.

Regency Foyer, Ballroom Level, West Tower

**Plenary Reception**



# Schedule of Events

Order of Levels (top to bottom): **Skyway Level** | **Lobby Level** | **Concourse Level** | **Ballroom Level** | **Riverside Exhibit Level**

## 11:00 A.M. - 12:00 P.M.

Water Tower, Concourse Level, West Tower

**GI Translational  
Medicine Working  
Group (Working Group  
Members Only)**

## 12:00 P.M. - 2:00 P.M.

Regency A-C, Ballroom Level, West Tower

**PLENARY II (GENERAL)**

## 2:15 P.M. - 3:15 P.M.

Gold Coast, Concourse Level, West Tower

**NCORP/MU-NCORP Site  
PI Meeting**

## 2:15 P.M. - 4:15 P.M.

Comiskey, Concourse Level, West Tower

**GI Working Group  
Meeting (Working  
Group Members Only)**

## 2:30 P.M. - 4:00 P.M.

San Francisco, Ballroom Level, West Tower

**VA Working Group  
(Invitation Only)**

## 2:30 P.M. - 6:30 P.M.

Crystal A, Lobby Level, West Tower

**GU Organ Site Meeting  
(Working Group  
Members Only)**

## 3:00 P.M. - 5:00 P.M.

New Orleans, Ballroom Level, West Tower

**ORP Planning Meeting  
(Committee Members  
Only)**

## 4:00 P.M. - 6:00 P.M.

Crystal C, Lobby Level, West Tower

**Recruitment and  
Retention Committee  
Meeting**

## 4:00 P.M. - 6:00 P.M.

Water Tower, Concourse Level, West Tower

**Leukemia Working  
Group Meeting  
(Working  
Group Members Only)**

## 4:00 P.M. - 6:30 P.M.

Acapulco, Ballroom Level, West Tower

**Movie Screening:  
Cancer Rebellion**

## 4:00 P.M. - 7:00 P.M.

Regency B, Ballroom Level, West Tower

**LYMPHOMA  
COMMITTEE**

## 4:30 P.M. - 6:30 P.M.

Columbian, Concourse Level, West Tower

**Pharmaceutical  
Sciences Committee**

## 4:30 P.M. - 6:30 P.M.

Crystal B, Lobby Level, West Tower

**GI COMMITTEE**

## 6:00 P.M. - 7:00 P.M.

**Executive Reception  
(Invitation Only)**

## 6:45 P.M. - 8:00 P.M.

Regency CD, Ballroom Level, West Tower

**Reception**

## Saturday, October 14, 2017

**Group Meeting Registration & Information Desk**

**7:00 a.m. - 5:00 p.m. - Regency Foyer,  
Ballroom Level, West Tower**

**Hope Foundation Information Desk**

**8:00 a.m. - 5:00 p.m. - Regency Foyer,  
Ballroom Level, West Tower**

## 7:15 A.M. - 8:00 A.M.

Regency B, Ballroom Level, West Tower

**Board of Governors  
(Board Members Only)**

## 8:15 A.M. - 9:15 A.M.

Regency B, Ballroom Level, West Tower

**Committee Chairs  
(Committee  
Chairs Only)**

## 9:30 A.M. - 11:30 A.M.

Crystal C, Lobby Level, West Tower

**RADIATION ONCOLOGY  
COMMITTEE**

## 9:30 A.M. - 11:30 A.M.

Regency C, Ballroom Level, West Tower

**LEUKEMIA COMMITTEE**

## 9:30 A.M. - 12:30 P.M.

Regency A, Ballroom Level, West Tower


**GU COMMITTEE**

## 9:30 A.M. - 12:30 P.M.

Regency D, Ballroom Level, West Tower

**BREAST COMMITTEE**

# Chicago Special Events



*All SWOG  
members are  
welcome!*

**Wednesday,  
October 11**

**1:00 to  
5:00 p.m.  
(Check-in  
at 12:30 p.m.)**

**Regency A+B**

*Attendees  
receive up to  
four hours of  
credits from  
the Society of  
Clinical Research  
Associates  
(SOCRA)*

*All SWOG  
members are  
welcome, but  
space is limited  
and pre-  
registration is  
required.*

**Thursday,  
October 12**

**5:00 to 7:00 p.m.**

**LOCATION TO  
COME**

**3<sup>RD</sup> Annual**

## **SWOG NCORP Research Base Clinical Trials Workshop**

A training course on clinical trials in cancer care delivery, survivorship, prevention and epidemiology, and symptom control and quality of life

- Attendees will gain new knowledge and perspective on conducting NCORP studies
- Unique presentations by experts from
  - ✓ SWOG Statistics and Data Management Center at Fred Hutchinson Cancer Research Center and Cancer Research And Biostatistics
  - ✓ The National Cancer Institute's Division of Cancer Prevention, Healthcare and Delivery Research Program, and Center to Reduce Cancer Health Disparities,
  - ✓ MD Anderson Cancer Center
- Breakout discussion sessions on topics specific to practical study administration

## **Developing Cultural Competency in Clinical Trials Workshop**

An education session designed to enhance the level of cultural competence of SWOG research members, with the goal of increasing diversity among clinical trial participants.



**PRESENTER:**

**Marvella Ford, PhD**

*Professor, Department of Public Health  
Sciences*

*Associate Director, Population Sciences and  
Cancer Disparities,*

*Hollings Cancer Center*

*SmartState Endowed Chair, Cancer  
Disparities Research*

*Medical University of South Carolina*

*Sponsored by the SWOG Recruitment  
and Retention Committee*

**NCI**


Community Oncology  
Research Program

**THE HOPE FOUNDATION**

*Because answers to cancers come from clinical trials*

**SWOG**  Leading cancer research. Together.





*Light refreshments will be provided*

# Bonus Event!

Free Movie Screening

Friday, Oct. 13 | 4:00 - 6:30 p.m.

Acapulco, Ballroom Level, West Tower  
Open to All Members

Come see *Cancer Rebellion*, a documentary that chronicles the experience of teen cancer patients from across America.

Filmmaker **Hernan Barangan**, who was treated for acute myelogenous leukemia at 15, logged over 25,000 miles in all 50 states to document teens' stories and will speak at the screening.



We fund great ideas.  
You can, too.

Because answers to  
cancers come from  
clinical trials.

The Hope Foundation is a 501c3 public charity supporting physicians, clinical researchers, scientists, and patient advocates in their pursuit of new and impactful approaches to treating, preventing and detecting cancer, and in bettering the quality of life for both cancer patients and cancer survivors.

Please give today: [thehopefoundation.org/donate](http://thehopefoundation.org/donate)

[SWOG.ORG](http://SWOG.ORG) / [THEHOPEFOUNDATION.ORG](http://THEHOPEFOUNDATION.ORG)

SUPPORTING THE IMPORTANT WORK OF **SWOG**

 @SWOG/@SUPPORTINGSWOG

THE HOPE FOUNDATION

*Because answers to cancers come from clinical trials*

LEARN MORE AT [THEHOPEFOUNDATION.ORG](http://THEHOPEFOUNDATION.ORG)

## SWOG Administrative Committees

### ***Conflict Management***

*Paul Okunieff, MD*

### ***Data and Safety Monitoring***

*Lawrence E. Flaherty, MD*

### ***Publications***

*Hagen Kennecke, MD*

### ***Professional Review***

*Primo N. Lara, Jr., MD*

## SWOG Research Support Committees

### ***Adolescents and Young Adults***

*Mark A. Lewis, MD*

### ***Digital Engagement***

*Don S. Dizon, MD*

### ***Imaging***

*Lawrence H. Schwartz, MD*

### ***Oncology Research Professionals***

*Keisha Humphries, RN, RSN*

### ***Patient Advocates***

*Rick Bangs, MBA*

### ***Pharmaceutical Sciences***

***Co-Chair*** *Siu-Fun Wong, MD*

***Co-Chair*** *Susan Kadlubar, MD*

### ***Radiation Oncology***

*Paul Okunieff, MD*

### ***Recruitment and Retention***

*Elise Cook, MD*

### ***Surgery***

*George H. Yoo, MD*

### ***Future Meeting Dates***

#### **2018**

April 11-14

San Francisco, CA

Oct 3-6

Chicago, IL

#### **2019**

April 24-27

San Francisco, CA

Oct 2-5

Chicago, IL

#### **2020**

April 22-25

San Francisco, CA

Sep 23-26

Chicago, IL



# Barlogie-Salmon Myeloma Committee

## Leadership

Chair: ..... Robert Z. Orlowski, M.D., Ph.D.  
 Vice-Chair: ..... Brian G.M. Durie, M.D.  
 Executive Officer: ..... Susan M. O'Brien, M.D.  
 Statisticians: ..... Antje Hoering, Ph.D.  
 ..... Rachael Sexton, M.S.  
 ..... Kari Chansky, M.S.

## Scientific Leadership

Translational Medicine: ..... Brian A. Walker, B.Sc., Ph.D.  
 Radiation: ..... TBD  
 Surgery: ..... J. Sybil Biermann, M.D.  
 Imaging: ..... Saad Z. Usmani, M.D.  
 ..... Eric M. Rohren, M.D., Ph.D.  
 Pathology: ..... Robert B. Lersbach, M.D., Ph.D.  
 Early Therapeutics: ..... Frits van Rhee, M.D., Ph.D.

## Designates

NCORP Representative: ..... George F. Geils, Jr., M.D.  
 Data Coordinators: ..... Jeri Jardine  
 ..... Laura Kingsbury, M.R.T.  
 ..... Sean O'Bryan  
 ..... Joanna Dur  
 Oncology Research Professionals:  
 CRA: ..... TBD  
 Nurses: ..... Deborah A. Shaw, R.N.  
 ..... Teresa Witcher, B.S.N., R.N.  
 Patient Advocate: ..... Jack Aiello, M.S.  
 Pharmaceutical Science: ..... Lara M. Au, Pharm.D.  
 ..... Craig Elg, Pharm.D.  
 Protocol Coordinator: ..... TBD

## Time/Location

Friday, October 13, 2017 7:30 a.m. - 9:30 a.m.  
 Crystal A, Lobby Level, West Tower

## Active Studies

**S1211**, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S.Z. Usmani, S. Ailawadhi, and B.Lipe. Activated: 10/12/12. Temporarily closed to accrual: 6/2/2016.

**CTSU/E1A11**, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed

Symptomatic Multiple Myeloma (ENDURANCE)." Dr. J. Zonder. Activated by ECOG: 11/13/13; Activated by SWOG: 2/1/14.

**CTSU/A061402**, "Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy." Dr. E. Manasanch. Pre-Activated by SWOG: 11/15/2016; Activated by Alliance: 12/23/2015.

## Closed Studies

**S1304**, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease." Drs. S.A. Ailawadhi, M.H. Abidi, S. Lentzsch, R.Z. Orlowski, and E. M. Rohren. Activated: 10/18/13. Closed: 5/15/2016.

**CTSU/E3A06**, "Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma." Dr. M. Dhodapkar. Activated by ECOG: 10/5/2010; Activated by SWOG: 2/1/11. Closed: 7/27/17.

## Proposed Studies

**S1611**, "A Phase II Non-Randomized Study of 11-1F4 Chimeric Monoclonal Ab added to standard treatment in Untreated Subjects with Light Chain (AL) Amyloidosis." Dr. S. Lentzsch.

**S1702**, "A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis." Dr. E. Scott.

**S1803**, "Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Dr. A. Krishnan.

**XXXXX**, "Randomized Phase II Multicenter Non-Inferiority Trial of Rivaroxaban 10 mg Daily Versus Low Molecular Weight Heparin for Prevention of Thromboembolism in Patients Being Treated with an Immunomodulatory-Based Regimen for Multiple Myeloma." David Calverley, Jamie Meyers, and Emma Scott.

## Open Forum Discussion

## Working Groups

Amyloidosis Working Group update  
 Waldenström's Working Group update  
 Myeloma Translational Medicine Subcommittee update

## Barlogie-Salmon Myeloma Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1211	E1A11	E3A06
Arkansas, U of	—	1	—
Baylor College	—	6	—
Beaumont NCORP	—	4	—
CORA NCORP	—	1	—
CRC West MI NCORP	1	—	—
City of Hope Med Ctr	7	—	—
Cleveland Clinic OH	10	—	—
Columbus NCORP	4	—	—
Cookeville Reg MC	—	4	—
Davis, U of CA	—	9	—
Dayton NCORP	1	2	—
Essentia Hlth NCORP	1	—	—
Greenville NCORP	—	—	6
Hawaii MU-NCORP	—	1	—
Heartland NCORP	3	—	—
Henry Ford Hosp	—	8	1
Irvine, U of CA	—	5	1
Kaiser Perm NCORP	—	17	—
Kansas City NCORP	1	—	—
Kansas, U of	13	1	15
Loyola University	3	4	—
MD Anderson CC	10	—	—
Michigan CRC NCORP	5	—	—
Michigan, U of	—	1	—
Montana NCORP	—	3	2
Oklahoma, Univ of	1	—	—
Oregon Hlth Sci Univ	—	3	—
Ozarks NCORP	2	6	1
PCRC NCORP	—	—	1
Providence Hosp	4	5	2
Rochester, Univ of	7	—	—
San Antonio, U of TX	15	6	—
So Calif, U of	2	—	—
Southeast COR NCORP	4	5	—
Sutter Cancer RC	—	5	—
Tennessee, U of	—	—	1
Tulane University	1	—	2
VAMC Kansas City	—	2	—
Wayne State Univ	3	9	—
Yale University	—	20	3
Alliance	10	—	—
ECOG-ACRIN	31	—	—
NRG	3	—	—
<b>Total</b>	<b>142</b>	<b>128</b>	<b>35</b>



# Breast Committee

## Leadership

Chair: ..... Lajos Pusztai, M.D. D.Phil.  
 Vice-Chair: ..... Debu Tripathy, M.D.  
 Executive Officer: ..... Julie R. Gralow, M.D.  
 Statisticians: ..... William E. Barlow, Ph.D.  
 ..... Danika Lew, M.A.  
 ..... Jieling Miao, M.S.

## Scientific Leadership

Translational Medicine: ..... Daniel F. Hayes, M.D.  
 Radiation Oncology: ..... Reshma Jaggi, M.D.  
 Surgery: ..... Christine Lee, M.D.  
 Imaging: ..... Anne F. Schott, M.D.  
 ..... Wei Tse Yang, M.B.B.S.  
 Pathology: ..... Allen M. Gown, M.D.  
 ..... Peggy L. Porter, M.D.  
 Early Therapeutics: ..... George Somlo, M.D.

## Designates

Cancer Control Liaisons: ..... Carol J. Fabian, M.D. (Cancer Survivorship)  
 ..... Dawn L. Hershman, M.D. (Cancer Care Delivery)  
 ..... Banu Arun, M.D. (Prevention)  
 ..... Helen K. Chew, M.D. (Symptom Control & QOL)  
 NCORP Representative: ..... Melanie E. Royce, M.D., Ph.D.  
 Data Coordinators: ..... Jennie Barrett  
 ..... Jacqueline Scurlock  
 ..... Sean O'Bryan  
 ..... Larry Kaye  
 ..... Iris Syquia  
 Oncology Research Professionals:  
 CRA: ..... Karyn N. Hart, C.C.R.P.  
 Nurses: ..... Dorothy Coleman, R.N., M.S.  
 ..... Kathy L. Czaplicki, R.N., M.S.N.  
 ..... Crystal L. Watson, R.N.  
 Patient Advocate: ..... Ginny Mason  
 ..... Elda Railey, R.N., B.S.N.  
 Pharmaceutical Science: ..... Jessie Modlin, Pharm.D.  
 ..... Rivka Siden, Pharm.D.  
 Protocol Coordinator: ..... Veronica Garcia

## Time/Location

Saturday, October 14, 2017 9:30 a.m. - 12:30 p.m.  
 Regency D, Ballroom Level, West Tower

## Agenda

**9:30 – 9:35 a.m.:** Welcome and Introductions – Lajos Pusztai, M.D. D.Phil and Debu Tripathy, M.D.

**9:35 – 10:35 a.m.:** Breast Committee Mini-Symposium “The challenge of immunotherapy in breast cancer”

**9:35 – 9:55 a.m.:** Biomarkers of response to IO therapy - Sarah Warren, M.D. Nanostring

**9:55 – 10:15 a.m.:** The landscape of immunotherapy trials in breast cancer and current NCTN initiatives- Heather McArthur, M.D. Cedars Sinai Medical Center

**10:15 – 10:35 a.m.:** SWOG Immunotherapy Trials - Erin Cobain, M.D. University of Michigan

**10:35 – 10:45 a.m.:** Panel discussion and audience Q & A

**10:45 – 10:55 a.m.:** Publications update - Bill Barlow, Ph.D.

**10:55 – 11:30 a.m.:** Update of open SWOG and CTSU trials - All

**11:30 – 11:45 a.m.:** Studies in Development - All

**11:45 – 12:00 p.m.:** Reports from Committee Liaisons  
 Radiotherapy - Reshma Jaggi, M.D.  
 Surgery - Christine Lee, M.D.  
 Cancer Survivorship - Carol Fabian, M.D.  
 Cancer Care Delivery - Dawn Hershman, M.D.  
 Prevention – Banu Arun, M.D.  
 NCORP (NCI Community Oncology Research Program) – Melanie Royce, M.D.  
 Patient Advocate – Ginny Mason and Elda Railey

**12:00 – 12:25 p.m.:** Translational Medicine Sub-Cmte – Daniel Hayes, M.D.

**12:25 – 12:30 p.m.:** New Business – All

**12:30 p.m.:** Closing Comments and Adjourn

## Active Studies

**S1207**, “Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.” Drs. Chavez-MacGregor, Rastogi, Pusztai.  
 Activated: 9/3/13.

# Breast Committee

**S1416**, "Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple Negative Breast Cancer (TNBC) and BRCA Mutation-Associated Breast Cancer." Drs. Rodler and Sharma. Activated: 7/7/16.

**S1418**, "A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with  $\geq 1$  cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy." Drs. Puszta and Mammen. Activated: 11/15/16.

**CTSU/A011106**, "Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study." Dr. Ma. SWOG Champion: Dr. Forero. Activated: 12/13/13.

**CTSU/A011202**, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 2/7/14.

**CTSU/A011502**, "A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial." Dr. Chen. SWOG Champion: Dr. Symington. Activated: 12/8/16.

**CTSU/EA1131**, "A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy." Dr. Mayer. SWOG Champion: Dr. Rodler. Activated: 4/29/15.

**CTSU/E2112**, "A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer." Dr. Connolly. SWOG Champion: Dr. Royce. Activated: 3/29/14.

**CTSU/NRG-BR002**, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14.

**CTSU/NRG-BR003**, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 6/26/15.

## Active and Developing Cancer Control Studies

**S1415CD**, "A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia – Trial Assessing CSF Prescribing Effectiveness and Risk (TRACER)". Drs. Ramsey, Hershman, Lyman and Sullivan. Activated: 10/7/16.

**S1501**, "Prospective Evaluation of Carvedilol vs No Treatment in Prevention of Cardiac Dysfunction in Women with Metastatic HER2+ Breast Cancer." Drs. Floyd and Leja. Activation: 9/15/17.

**CTSU/A011401**, "Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer." Drs. Ligibel and Hershman. Activated: 8/29/16.

**CTSU/E1Z11**, "A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)." Dr. Stearns. Activated: 5/21/13.

## Closed Studies

**S1007**, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer." Drs. Kalinsky, Gralow, Meric-Bernstam, Hortobagyi, Albain and Barlow. Activated: 1/15/11. Closed: 10/1/15.

**CTSU/A011203**, "A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer." Dr. Goetz. Activated: 3/6/15. Closed: 5/19/17

**CTSU/E4112**, "Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)." Drs. Leman, Khan and So. Activated: 2/17/15. Closed: 4/20/16

**CTSU/Z11102**, "Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)." Dr. Boughey. Activated: 7/23/12. Closed: 8/19/16.

## Closed Cancer Control Studies

**S1200**, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer." Drs. Hershman and Crew. Activated: 3/27/12. Closed 2/15/17.

# Breast Committee

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13. Closed: 2/15/17.

## Rare Cancers Active Studies

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 1/13/17.

**CTSU/EAY131**, "Molecular Analysis for Therapy Choice (MATCH)." Drs. Chen and Flaherty. Activated: 8/12/15.

## Studies in Development

**S1706**, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jagsi.

**S1719**, "PeRsistently Elevated CTCs in Chemotherapy Refractory Metastatic Breast Cancer Treated with Combination Immune CHECKpoint Inhibition (PRE-CHEK)." Drs. Cobain and Hayes.

Phase II Randomized Trial to Evaluate the Safety and Efficacy of Pertuzumab and Trastuzumab Plus Ribociclib and an Aromatase Inhibitor or Fulvestrant as Therapy for HER2-positive and HR-positive Metastatic Breast Cancer (PETRA). Drs. Giordano and Lu.

Single Arm Treatment De-escalation Trial for Clinical Stage I-IIIa, HER-2 Positive, Invasive Breast Cancer that Achieved Pathologic Complete Response (ypT0/is ypN0) After Neoadjuvant Chemotherapy and HER-2-Targeted Therapy. Drs. Sanft and Elias.

## GO MOBILE AT THE MEETING

*We're excited to announce we have a brand new mobile guide for you to use on Guidebook! Get the guide to access the most up-to-date information about our event, including schedules, maps, and much more.*

Get our guide here: <https://guidebook.com/g/swogfall2017>

Android and iOS users:

1. Tap the "Download" button to download the free Guidebook app
2. Open Guidebook and you can find our "SWOG Fall 2017 Group Meeting" guide

See you there!

— SWOG Spring 2017  
Group Meeting  
Team



COMPATIBLE WITH IPHONES, IPADS, ANDROID AND BLACKBERRY DEVICES



# More than \$300,000 To VA Medical Centers Since 2015

To Improve Veterans' Access to National Clinical Trials  
Network Cancer Clinical Trials

**SWOG**  Leading cancer research. Together.

THE HOPE FOUNDATION

*Because answers to cancers come from clinical trials*



# Breast Committee

## Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1007	S1207	S1416	S1418	A011106	A011202	A011203	A011401	A011502	A221405	B51	B52	B55	E1Z11	E2112	E4112	EA1131	NRGBR003	Z11102
Arizona MC, U of	—	9	—	—	15	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Arkansas, U of	22	15	—	2	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—
Atlanta Reg CCOP	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Baptist MU-NCORP	1	4	1	—	9	1	1	1	—	—	—	—	—	1	1	—	—	1	—
Bay Area NCORP	3	1	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Baylor Univ Med Ctr	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Beaumont NCORP	30	7	1	—	—	—	—	—	—	—	—	—	—	3	—	—	—	—	1
Boston Medical Ctr	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Brooke Army Med Ctr	2	—	—	1	—	—	—	—	—	—	—	—	1	—	—	—	2	—	—
CORA NCORP	16	12	—	3	1	—	—	—	—	—	2	—	—	1	3	—	—	—	—
CRC West MI NCORP	7	6	2	2	—	—	—	1	—	—	—	—	—	2	—	—	—	—	—
Carle CC NCORP	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cedars-Sinai Med Ctr	8	9	—	—	—	—	—	—	—	—	—	3	5	—	—	—	—	—	—
Cincinnati MC, U of	3	8	—	—	—	—	—	—	—	—	—	1	—	4	—	—	—	—	—
City of Hope Med Ctr	45	16	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cleveland Clinic OH	27	12	—	—	—	—	—	—	—	—	—	—	1	—	11	—	—	5	—
Colorado, U of	29	11	—	—	4	22	—	6	2	1	1	—	1	2	—	—	—	—	6
Columbia MU-NCORP	16	4	—	—	—	—	—	—	—	—	—	1	—	16	2	—	—	—	—
Columbia University	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Columbus NCORP	18	13	5	2	—	—	—	—	—	—	—	—	—	2	—	—	—	—	—
Cookeville Reg MC	7	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—
Davis, U of CA	8	7	5	1	—	—	—	—	2	—	—	—	—	1	—	—	—	—	—
Dayton NCORP	6	5	4	—	2	—	—	1	—	—	—	—	—	2	—	—	—	—	—
Desert Hospital	2	1	—	—	—	2	—	—	—	—	3	—	—	—	—	—	—	—	—
Essentia Hlth NCORP	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fred Hutchinson CRC	6	18	5	1	—	—	—	1	—	1	—	—	1	—	1	—	—	—	—
Georgia NCORP	—	1	—	1	—	—	—	—	—	—	—	—	—	8	—	—	—	—	—
Greenville NCORP	4	—	2	—	—	—	—	—	—	—	—	—	—	12	—	—	—	—	—
Gulf Coast MBCCOP	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gulf South MU-NCORP	6	15	—	—	—	—	—	—	—	—	—	—	—	5	—	—	—	1	—
H Lee Moffitt CC	2	5	—	—	—	1	—	—	2	—	—	—	—	—	—	11	—	—	—
Harrington CC	2	1	—	—	—	3	—	—	—	—	—	—	—	—	—	—	—	—	—
Harrison Medical Ctr	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hawaii MU-NCORP	12	8	—	—	—	—	—	—	—	—	—	—	—	16	—	—	—	—	—
Heartland NCORP	12	15	3	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Henry Ford Hosp	11	4	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—
INC, Bogota	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
INCan	96	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Intermountain MC	5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Irvine, U of CA	21	8	—	—	2	—	—	2	—	—	—	—	—	—	—	—	—	—	—
Kaiser Perm NCORP	89	33	—	—	—	1	2	11	—	—	—	—	2	28	—	1	—	4	—
Kansas City NCORP	11	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kansas, U of	33	37	—	2	—	4	—	5	—	—	—	1	1	—	7	—	—	—	—
Kentucky, U of	21	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
King Faisal Spec Ho	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lahey Hosp & Med Ctr	19	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

## Breast Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1007	S1207	S1416	S1418	A011106	A011202	A011203	A011401	A011502	A221405	B51	B52	B55	E1Z11	E2112	E4112	EA1131	NRGBR003	Z11102
Loma Linda Univ	5	7	—	—	—	2	—	—	—	—	2	1	—	—	—	—	—	—	—
Loyola University	30	11	1	—	—	—	—	3	—	—	1	1	—	—	—	—	—	—	—
MD Anderson CC	147	55	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
MUSC MU-NCORP	21	8	4	—	1	—	—	—	—	—	—	—	—	5	—	—	—	—	—
Madigan Army Med Ctr	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Methodist Hospital	7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3
Michigan CRC NCORP	44	17	4	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Michigan, U of	29	16	2	—	—	—	—	2	—	—	—	—	1	11	—	—	—	3	—
Mississippi, Univ of	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Montana NCORP	9	6	—	—	—	—	—	—	—	—	—	—	—	4	—	—	—	—	—
National Cancer Ctr	143	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Nevada CRF NCORP	1	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
New Mexico MU-NCORP	27	17	5	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Northwest NCORP	28	3	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—
Northwestern Univ	3	8	—	—	—	—	4	—	—	—	—	—	—	—	2	—	—	1	—
Oklahoma, Univ of	8	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Orange Reg Med Ctr	—	—	—	2	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—
Oregon Hlth Sci Univ	4	17	2	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—
Ozarks NCORP	9	12	2	—	—	—	—	—	—	—	—	—	—	9	—	—	—	3	—
PCRC NCORP	31	14	—	2	—	—	—	1	—	—	—	—	—	6	—	—	—	1	—
Providence Hosp	8	7	—	1	—	2	—	2	—	—	2	—	1	2	—	—	—	3	—
Rochester, Univ of	7	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2	—
San Antonio, U of TX	25	19	—	—	1	—	—	—	—	—	—	—	1	—	4	—	—	3	—
San Diego, U of CA	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1
So Calif, U of	15	8	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—
Southeast COR NCORP	31	21	4	3	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—
St Louis CCOP	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
St Louis University	1	1	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sutter Cancer RC	—	9	1	—	4	—	—	1	—	—	1	—	—	—	—	—	—	2	—
Tennessee, U of	5	5	—	—	—	4	—	—	—	—	3	—	—	—	—	—	—	—	—
Tulane Univ MBCCOP	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Tulane University	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Univ of Louisville	8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Upstate Carolina	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Utah, U of	18	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Wayne State Univ	23	11	—	—	—	6	—	—	—	—	—	—	2	—	3	—	—	5	3
Wichita NCORP	57	27	2	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Wisconsin NCORP	—	1	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Yale University	24	32	—	—	—	—	—	21	1	—	—	—	—	2	1	7	2	4	—
Alliance	526	203	20	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
CCTG	328	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
ECOG-ACRIN	713	193	12	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
GEICAM	792	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
NRG	265	251	21	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
UNICANCER	921	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
<b>Total</b>	<b>4,982</b>	<b>1,294</b>	<b>112</b>	<b>42</b>	<b>41</b>	<b>51</b>	<b>7</b>	<b>59</b>	<b>8</b>	<b>2</b>	<b>16</b>	<b>9</b>	<b>18</b>	<b>142</b>	<b>36</b>	<b>20</b>	<b>4</b>	<b>38</b>	<b>14</b>

# Cancer Control and Prevention Committees

## Leadership

Vice-Chair NCORP: ..... Dawn L. Hershman, M.D., M.S.  
 Cancer Care Delivery Cmte Co-Chairs: ..... Dawn L. Hershman, M.D., M.S.  
 ..... Scott D. Ramsey, M.D., Ph.D.  
 Cancer Survivorship Cmte Co-Chairs: ..... Robert S. Krouse, M.D., F.A.C.S.  
 ..... TBD  
 Prevention and Epidemiology Cmte Co-Chairs: ..... Banu Arun, M.D.  
 ..... Marian Neuhouser, Ph.D., R.D.  
 Symptom Control & QOL Cmte Co-Chairs: ..... Michael Fisch, M.D., Ph.D.  
 ..... Norah Lynn Henry, M.D., Ph.D.  
 Executive Officers: ..... Katherine D. Crew, M.D. (Prevention, Survivorship)  
 ..... Gary Lyman, M.D. (CCD, Symptom Control & QOL)  
 Senior Advisor: ..... Frank L. Meyskens, Jr., M.D.  
 Statisticians: ..... Garnet Anderson, Ph.D.  
 ..... William E. Barlow, Ph.D.  
 ..... Katherine Guthrie, Ph.D.  
 ..... Cathy Tangen, Dr.P.H.  
 ..... Joseph M. Unger, Ph.D.  
 ..... Riha Vaidya, Ph.D.  
 ..... Kathryn B. Arnold, M.S.  
 ..... Amy K. Darke, M.S.  
 ..... Phyllis J. Goodman, M.S.  
 ..... Danika Lew, M.A.  
 ..... Edward Mayerson, M.S.  
 ..... Anna Moseley, M.S.  
 ..... Cathee Till, M.S.  
 Administrative Lead Statistics & Data Management: . Monica Yee, C.C.R.P.

## Scientific Leadership

NCORP Representative: ..... Mark A. O'Rourke, M.D.  
 Radiation Oncology Committee: ..... Louis "Sandy" Constine, M.D.  
 Surgery Committee: ..... Robert S. Krouse, M.D. FACS  
 Translational Medicine: ..... James (Jimmy) Rae, Ph.D.  
 Liaisons:  
 Breast Committee: ..... TBD (Survivorship)  
 ..... Norah Lynn Henry, M.D., Ph.D. (Symptom Control & QOL)  
 ..... Dawn Hershman, M.D., M.S. (CCD)  
 ..... Banu Arun, M.D. (Prevention)  
 CCDR Committee: ..... Afsaneh Barzi, M.D. (GI)  
 Gastrointestinal Committee Colon: ..... Jason, Zell, D.O. (Prevention)  
 Genitourinary Committee: ..... Peter J. Van Veldhuizen, Jr., M.D.  
 International Liaison: ..... Kathy S. Albain, M.D.  
 Lung Committee: ..... Gary E. Goodman, M.D.  
 Melanoma Committee: ..... Sancy Leachman, M.D., Ph.D.  
 Recruitment and Retention Committee: ..... Elise Cook, M.D.

## Designates

Oncology Research Professionals  
 Clinical Research Associates: ..... Amanda R. Dinsdale, M.H.A., C.C.R.C.  
 ..... Connie Szczepanek, R.N.  
 ..... Mindy Whisnant, C.C.R.P.  
 Nurses: ..... Joan Long, R.N.  
 ..... Michaela S. Sherbeck, R.N.  
 ..... Joyce N. Tull, R.N.  
 Pharmaceutical Sciences Committee: ..... Manj Randhawa, Pharm.D.  
 ..... Siu-Fun Wong, Pharm.D.  
 ..... Susan A. Kadlubar, Ph.D.  
 SDMC Data Coordinators and Staff: ..... Heidi Dong  
 ..... Sam Dzingile  
 ..... Diane Liggett, C.C.R.P.  
 ..... Jennifer Patterson  
 ..... Roxanne Topacio, C.C.R.P.  
 ..... Monica Yee, C.C.R.P.  
 SDMC Recruitment and Retention Specialist: ..... Jennifer Maeser, M.S.  
 Patient Advocates: ..... Barbara Segarra-Vazquez, D.H.Sc. (CCD)  
 ..... Amy Geschwender, Ph.D. (Symptom Control & QOL)  
 ..... Hartley "Lee" M. Jones, M.B.A. (Survivorship)  
 ..... Sandra Jean Hamilton, R.N., M.E.D. (Recruitment & Retention)  
 ..... Cheryl Jernigan, CPA (Prevention & Epidemiology)  
 Protocol Coordinator (Cancer Care Delivery;  
 Prevention and Epidemiology Committees): ..... Patricia O'Kane  
 Protocol Coordinator (Cancer Survivorship  
 Committee): ..... Nicki Trevino  
 Protocol Coordinator (Symptom Control and  
 Quality of Life Committee): ..... Dawne Wenzel, M.A., M.S.



# Cancer Control and Prevention Committees

## Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S0820	A211102	A211201	EA1141
Baptist MU-NCORP	1	—	—	—
Brooke Army Med Ctr	2	—	—	—
CORA NCORP	2	—	—	—
City of Hope Med Ctr	1	2	—	—
Colorado, U of	2	—	—	—
Columbia MU-NCORP	1	1	2	—
Columbus NCORP	3	—	—	—
Dayton NCORP	1	—	—	—
Essentia Hlth NCORP	3	—	—	—
Georgia NCORP	2	—	—	—
Hawaii MU-NCORP	6	—	—	—
Heartland NCORP	2	—	—	—
Irvine, U of CA	15	—	—	—
Kaiser Perm NCORP	21	—	9	—
Kansas, U of	3	—	—	—
Lahey Hosp & Med Ctr	—	—	1	7
Loma Linda Univ	1	—	—	—
Loyola University	1	—	—	—
MAVERIC	3	—	—	—
MD Anderson CC	8	—	—	—
Michigan CRC NCORP	4	—	—	—
Michigan, U of	—	—	2	—
Mississippi, Univ of	1	—	—	—
Northwest NCORP	3	—	—	—
Oklahoma, Univ of	1	—	—	—
Providence Hosp	1	—	—	—
San Antonio, U of TX	6	—	—	—
So Calif, U of	4	1	—	—
Southeast COR NCORP	1	—	—	—
Wayne State Univ	2	—	—	—
Wichita NCORP	10	—	—	—
Yale University	7	—	—	—
Alliance	14	—	—	—
ECOG-ACRIN	9	—	—	—
NRG	14	—	—	—
<b>Total</b>	<b>155</b>	<b>3</b>	<b>14</b>	<b>7</b>



# Cancer Care Delivery Committee

## Leadership

Co-Chairs: ..... Dawn L. Hershman, M.D., M.S.  
 ..... Scott D. Ramsey, M.D., Ph.D.

## Time/Location

Thursday, October 12, 2017 10:15 a.m. -12:15 p.m.  
 Regency D, Ballroom Level, West Tower

## Presentations/Concepts:

"How and when should we address value, access, and costs in the oncology clinic?" Jeffrey Peppercorn, M.D., MPH Associate Professor of Medicine, Massachusetts General Hospital, Harvard Medical School

"Randomized Trial of a Proactive Financial Navigation Intervention for Cancer Patients and Caregivers." Veena Shankaran, M.D., University of Washington

## Protocols in Development

**S1703**, "Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer." Melissa Accordino, M.D., Columbia University

## Concepts Approved by Triage

**S1705**, "Post Marketing Utilization and Effectiveness of Nivolumab and Pembiciclib in General Population." Afsaneh Barzi, M.D., University of Southern California; Alan Lyss, M.D., BJC

## Concepts in Development

Breast Cancer Endocrine Therapy Adherence Text Messaging Study ("BETA-Text"). Sarah Mougalian, M.D., Yale University (Primary committee is Symptom Control/QOL)

Health Insurance Coverage as a Potential Barrier to Enrollment in Cancer Clinical Trials. Josh Roth, Ph.D., MHA, Fred Hutchinson

Drug Interaction Screening Tool for Clinical Trial Enrollment. Dan Hertz, Pharm. D., Ph.D., University of Michigan College of Pharmacy

Optimizing Clinical Work Intensity Among Medical Oncologists. Matthew Hudson, Ph.D., MPH, Greenville Health System

Ancillary Study to Evaluate Patient & Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in SWOG 1400 (Lung-MAP). Josh Roth, Ph.D., MHA, Fred Hutchinson; Meghna Trivedi, M.D., Columbia University

## Active Studies

**S1415CD**, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)." Drs. S.D. Ramsey, D.L. Hershman, G.H. Lyman, S.D. Sullivan, A. Bansal and W. Barlow. Activated: 10/7/16.

**S1417CD**, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. Shankaran. Activated: 4/15/16.

## Updates on Closed Studies

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman, and Hwang. Activated: 8/29/13. Closed: 2/15/17.

## Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

**S1007**, Update on Quality of Life and Economic Analysis Sub-study of Breast protocol S1007. Bill Barlow, Ph.D.

**S1207**, Cost Effectiveness Analysis of "Phase III Randomized, Placebo-controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-risk, Hormone Receptor-positive and HER2 Negative Breast Cancer." Dr. Chavez-MacGregor.

SEED Funded Pilot Trial

A Pilot Project to Identify Techniques to Raise Awareness about SWOG Clinical Trials on an Online Oncologist Q&A Network. Nadine Housri, M.D.

# Cancer Care Delivery Committee

## Closed Studies

PCORI Project: A Structured Approach to Prioritizing Cancer Research Using Stakeholders and Value of Information (VOI). Dr. Ramsey and Dr. J. Carlson.

## Newly Funded And Ongoing Database/Grant Funded Projects

Long-term Consequences of Intervention Following Receipt of Finasteride or Placebo in the Prostate Cancer Prevention Trial. Joseph Unger, Ph.D.

## Newly Funded Database Studies

Development of Prognostic Risk Models for Response to Treatment and Placebo for Aromatase Inhibitor-Associated Musculoskeletal Symptoms. Lynn Henry, M.D., Ph.D.

Secondary Data Analysis of Adolescent & Young Adult Oncology (AYA) Patients in Relation

to their Body Mass Index (BMI) and Cancer Outcomes. Mark Lewis, M.D.

## Ongoing Database Pilot Studies

Ethnic disparities among participants in SWOG randomized clinical trials. Mariana Chavez, M.D. (Manuscript submitted)

Osteoporosis in Patients with Colorectal Cancer Enrolled on SWOG Trials. Afsaneh Barzi, M.D. (Manuscript submitted)

Evaluating the role of geographic location on outcomes among patients enrolled in SWOG trials. Banu Symington, M.D. (Manuscript in preparation)

## Cancer Care Delivery Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1204	S1415CD	S1417CD	A011104
Baptist MU-NCORP	—	27	—	—
Bay Area NCORP	92	7	—	—
Boston MC MBCCOP	33	—	—	—
Boston Medical Ctr	69	—	—	—
Brooke Army Med Ctr	—	—	—	2
CORA NCORP	—	8	2	—
CRC West MI NCORP	—	2	7	—
Carle CC NCORP	—	22	—	—
Columbia MUNCORP	266	33	9	—
Columbus NCORP	—	4	9	—
Cookeville Reg MC	—	—	—	2
Dayton NCORP	—	2	2	—
Desert Hospital	77	—	—	—
Essentia Hlth NCORP	—	14	—	—
Georgia NCORP	—	5	3	—
Greenville NCORP	542	35	8	—
Gulf South MUNCORP	426	11	—	—
Harrington CC	147	—	—	—
Hawaii MUNCORP	86	14	2	—
Heartland NCORP	—	116	9	—
Kaiser Perm NCORP	624	—	5	—
Loyola University	74	—	—	—
MD Anderson CC	354	—	—	—
Michigan CRC NCORP	—	9	3	—
Montana NCORP	33	13	1	—
New Mexico MU-NCORP	—	25	2	—
Northwest NCORP	—	10	—	—
Ozarks NCORP	—	72	—	—
PCRC NCORP	6	65	1	—
Providence Hosp	—	—	—	4
San Antonio, U of TX	146	—	—	—
Southeast COR NCORP	—	69	5	—
Sutter Cancer RC	10	—	—	—
VAMC Kansas City	107	—	—	—
Wayne State Univ	—	—	—	1
Wichita NCORP	—	40	2	—
Wisconsin NCORP	—	4	—	—
Alliance	—	52	1	—
ECOG-ACRIN	—	—	7	—
NRG	—	3	1	—
<b>Total</b>	<b>3,092</b>	<b>662</b>	<b>79</b>	<b>9</b>



# Cancer Survivorship Committee

## Leadership

Co-Chairs: ..... Robert S. Krouse, M.D.  
..... TBD

## Time/Location

Thursday, October 12, 2017 8:00 a.m. - 10:00 a.m.  
Regency D, Ballroom Level, West Tower

## Plenary

"Radiation therapy: Still a double-edged sword but trying to dull the normal tissue edge." Louis Constine, M.D.

Advocate Update: Rick Bangs

Introduction of new Cancer Survivorship Advocate – Lee Jones

## Approved Studies

**S1501**, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer." Justin Floyd, D.O. and Monika Leja, M.D.

## Update of Concepts Previously Proposed

**S1713**, "Text Intervention to Improve Cardiovascular Health In Breast Cancer Survivors." Dawn Hershman, M.D.

A fractional factorial trial to identify the most effective method to increase physical activity among colorectal cancer survivors. Heather Greenlee, N.D., Ph.D.

A Phase II trial of flibanserin to improve desire in women with cancer. Don Dizon, M.D.

A Personalized Dietary Intervention to Manage Bowel Dysfunction in Rectal Cancer Survivors. Virginia Sun, Ph.D., R.N.

Weight Loss in Newly Diagnosed Prostate Cancer. Jill Hamilton-Reeves, Ph.D., R.D.

## Activate Studies

**S1316**, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Robert Krouse, M.D. Activated: 3/9/15.

## Cancer Survivorship Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016

	S1316	E1Q11
Arizona MC, U of	8	—
Arkansas, U of	5	—
Baylor College	1	—
City of Hope Med Ctr	4	—
Columbia MU-NCORP	1	—
Hawaii MU-NCORP	—	4
Kansas, U of	12	—
MD Anderson CC	1	—
MUSC MU-NCORP	5	—
Michigan, U of	7	—
Oklahoma, Univ of	2	—
Tennessee, U of	14	—
Alliance	7	—
NRG	25	—
<b>Total</b>	<b>92</b>	<b>4</b>

## Subcommittee Updates

Sarcoma Survivorship: Lara Davis, M.D. and Laurence H. Baker, D.O.

New concept: Physical function in sarcoma survivors. Lara Davis, M.D., Kerri Winters-Stone, Ph.D., FACSM, Kim Templeton, M.D.

GU Survivorship: Peter Van Veldhuizen, M.D.

New concept: Testosterone replacement and exercise in hypogonadal prostate cancer survivors. Tanya Dorff, M.D.

Cardiovascular toxicity in renal cell carcinoma. Kerry Reding, Ph.D., M.P.H., R.N.

Palliative Medicine: Frank L. Meyskens, M.D.

Cancer Survivorship Website Project: Mark O'Rourke, M.D., Jennifer Klemp, Ph.D., and Marian Neuhaus, Ph.D., R.D.

Oncology Research Professionals Update: Jamie Myers APRN, Ph.D.

## Other Business

# Prevention & Epidemiology Committee

## Leadership

Co-Chairs: ..... Marian Neuhouser, Ph.D., R.D.  
 ..... Banu Arun, M.D.

## Time/Location

Thursday, October 12, 2017 12:30 p.m. - 2:30 p.m.  
 Regency D, Ballroom Level, West Tower

## Presentations

Welcome and Opening Comments: Marian Neuhouser and Banu Arun

Breast Density: Opportunities and Implications for Breast Cancer Prevention  
 Gretchen Gierach, Ph.D., MPH, National Cancer Institute

## Active Studies

**S0820**, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III." Drs. Zell, Brown, Lance, Krouse and Lipkin. Activated: 3/1/13.

NHLBI-MDS, The National Myelodysplastic Syndromes Natural History Study. Deirdre Hill, MPH, PhD, Study Champion.

## Closed Studies

**S0812**, "A Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High Risk for Breast Cancer, Phase IIB." Dr Crew. Activated 11/1/11; Closed 8/15/14.

## New Business

### Concepts approved by Triage

**S1711**, "Decision Support to Increase Chemoprevention Uptake Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ." Dr. Katherine Crew, M.D., M.S.

### Concepts Approved By NCORP Executive Committee:

A Randomized Study of Aspirin in Addition to Non-Steroidal AI in Obese Subjects with Breast Cancer. Andrew Brenner, M.D., Ph.D.

Phase II Study of Intraoperative Radiotherapy (IORT) for DCIS after Breast Conserving Surgery. Eileen Connolly, M.D.

Biology-Based Care in Testicular Cancer. Craig Nichols, M.D.

Exploratory Study to Evaluate Mammographic Density Changes in Patients Receiving Pembrolizumab in S1418. Banu Arun, MD

Assessment of Microbiota Composition Among Patients from SWOG S1119. C Xi, MD

### Concepts in Development

Project STOP (SWOG Tobacco program for Oncology Practice). Irene Tami-Maury, DMD, MSc, DrPH

Bazedoxifene + Conjugated Estrogen for Cancer Prevention in Women with Hot Flashes. Carol Fabian, MD and Lauren Nye, MD.

Melanoma Chemoprevention. Sancy Leachman, MD.

### Other Concepts to discuss

Open discussion



## SWOG FACTS

**The Hope Foundation is SWOG's philanthropic arm**, a non-profit public charity dedicated to raising funds to support SWOG's mission. It has contributed \$30 million to the group for research, travel, and training and education.


**Though SWOG originated in the southwestern U.S.**, it has long since become a national -- even international -- organization. Its core bases of operation are spread across the country, with key offices in Oregon, Texas, Washington, and Michigan.

**SWOG's Biorepository** holds more than 800,000 specimens with associated clinical data.

LEARN MORE AT [THEHOPEFOUNDATION.ORG](http://THEHOPEFOUNDATION.ORG)

# Save the date for the spring meeting

April 11-14  
San Francisco, CA



## Prevention & Epidemiology Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S0820	A211102	A211201	A211201
Baptist MU-NCORP	1	—	—	—
Brooke Army Med Ctr	2	—	—	—
CORA NCORP	2	—	—	—
City of Hope Med Ctr	1	2	—	—
Colorado, U of	2	—	—	—
Columbia MU-NCORP	1	1	2	—
Columbus NCORP	3	—	—	—
Dayton NCORP	1	—	—	—
Essentia Hlth NCORP	3	—	—	—
Georgia NCORP	2	—	—	—
Hawaii MU-NCORP	6	—	—	—
Heartland NCORP	2	—	—	—
Irvine, U of CA	15	—	—	—
Kaiser Perm NCORP	21	—	9	—
Kansas, U of	3	—	—	—
Lahey Hosp & Med Ctr	—	—	1	7
Loma Linda Univ	1	—	—	—
Loyola University	1	—	—	—
MAVERIC	3	—	—	—
MD Anderson CC	8	—	—	—
Michigan CRC NCORP	4	—	—	—
Michigan, U of	—	—	2	—
Mississippi, Univ of	1	—	—	—
Northwest NCORP	3	—	—	—
Oklahoma, Univ of	1	—	—	—
Providence Hosp	1	—	—	—
San Antonio, U of TX	6	—	—	—
So Calif, U of	4	—	—	—
Southeast COR NCORP	1	—	—	—
Wayne State Univ	2	—	—	—
Wichita NCORP	10	—	—	—
Yale University	7	—	—	—
Alliance	14	—	—	—
ECOG-ACRIN	9	—	—	—
NRG	14	—	—	—
<b>Total</b>	<b>155</b>	<b>3</b>	<b>14</b>	<b>7</b>



# Symptom Control & Quality of Life Committee

## Leadership

Co-Chairs: ..... Norah Lynn Henry, M.D., Ph.D.  
 ..... Michael J. Fisch, M.D., M.P.H.

## Time/Location

Friday, October 13, 2017 7:30 a.m. - 9:30 a.m.  
 Regency D, Ballroom Level, West Tower

## Feature Presentations (60 minutes)

Lynn Henry, M.D.: Exploring placebo effects in symptom management trials in SWOG

Lynne Nguyen, MPH: Plain talk about patient communications

## Trials under development (30 minutes)

"A Phase II randomized, placebo-controlled study to evaluate the use of vitamin K1 topical cream in patients with cutaneous toxicity caused by EGFR inhibitors." Dr. Wong.

"Cognitive Rehabilitation Intervention during Cancer Treatment: Emerging from the Haze." Jamie Myers, Ph.D., R.N., AOCNS and Dr. Asher, M.D.

## Other Discussion Topics (30 minutes)

Michael Fisch: Palliative care update

Other topics (TBD)

## Approved Trials (not yet active)

**S1600**, "Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Jill Hamilton-Reeves, Ph.D.

**S1614**, "Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors." Jessica Hwang, M.D., MPH.

## Closed Studies

**S1013**, "A Phase II Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy – EGFR18 (FACT-EGFR18) Questionnaire for EGFR-induced Skin Toxicities." Dr. Wong. Activated: 11/15/11. Closed to accrual 10/1/2016.

**S1200**, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer." Drs. Hershman and Crew. Activated: 4/1/12. Closed: 2/15/17.

**S1007**, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer." Drs. Kalinski and Gralow. Closed to accrual 10/1/15. Quality of Life and Economic Substudy closed to accrual 12/1/12.

**S1202**, "Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer." Drs. Henry and Schott. Activated: 5/15/13. Closed to accrual 10/1/15.

## Other Concepts in Development

"The Breast Endocrine Toxicity and Adherence (BETA) Trial." Sarah Mougalian, M.D.

**S1714**, "A prospective observational cohort study to assess the incidence of chemotherapy-related peripheral neuropathy." Meghna Trivedi, M.D.

"Cognitive Rehabilitation Intervention during Cancer Treatment: Emerging from the Haze." Arash Asher, M.D.; Jamie Myers, Ph.D., RN, AOCNS.

"A Phase II Randomized Placebo-Controlled Study to Evaluate the Use of vitamin K1 Topical Lotion in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors." Drs. Wong, Ryan, Wade, & Moynour.

## Other Studies with Symptom Control and QOL Component

**S1418**, "A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy." Drs. Puztai and Mammen. Activated: 11/15/16.

**S1207**, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer." Dr. Chavez-MacGregor. Activated: 9/1/13.

**S1404**, "A Phase III Randomized Study of MK-3475 (Pembrolizumab) versus High-Dose Interferon alpha-2b for Resected High-Risk Melanoma." Dr. Grossmann. Activated: 10/15/15. Closed: 8/15/17.

**S1718**, "Phase III Trial of Early versus Delayed Therapy with Ibrutinib, Venetoclax, and Obinutuzumab in Newly Diagnosed Asymptomatic High Risk Patients with CLL." Dr. Stephens.

# Symptom Control & Quality of Life Committee

**S1612**, "Patient-Centered Outcomes Concept: Investigation of Patient-Reported Outcomes and Geriatric Assessment to Inform Treatment Decisions and Trial Design." Laura C. Michaelis, MD and Roland B. Walter, MD.

**S1615/1712**, "A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in CML Patients with Evidence of Molecular Disease." Kendra Sweet, MD

**S1706**, "Veliparib and Radiation Therapy for Inflammatory Breast Cancer." Reshma Jaggi, MD.

**S1719**, "Persistently Elevated CTCs in Chemotherapy-Refractory Metastatic Breast Cancer Treated with Combination Immune Checkpoint Inhibitors (PRE-CHEK)." Erin Cobain, MD

**S1802**, "Standard Systemic Therapy (SST) Vs. SST plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Brian Chapin, MD

**S1708**, "A Randomized Trial of Aneteumab Ravtansine vs. Investigator's Choice (Vinorelbine or Gemcitabine) in Previously Treated Patients with Advanced Malignant Peritoneal Mesothelioma." Kanwal Raghav, MD

**S1717**, "Randomized Phase III Trial of the CancerTYPE ID Test in the Evaluation of Patients with Unknown Primary Cancer (CUP)." Sarah Yentz MD and Laurence Baker, D.O.

**CTSU/NRG-G1004**, "Colorectal Cancer Metastatic MSI-High Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with MSI-H Metastatic Colorectal Cancer." Michael Overman, MD

**CTSU/A021202**, "Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors." Dr. Phan. Activated: 6/21/13. Closed: 10/7/16.

**CTSU/A041202**, "A Randomized Phase III Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ( $\geq 65$  Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. Coutre. Activated: 12/9/13. Closed to accrual 5/16/16.

**CTSU/C30610**, "Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide." Drs. Gadgeel and Gaspar. Activated: 3/15/08.

**CTSU/C51101**, "A Randomized Phase II Trial of Myeloablative versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma." Dr. Mohile. Activated: 6/15/12.

**CTSU/C90203**, "A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer." Dr. Kim. Activated: 12/15/06. Closed to accrual 10/2/2015.

**CTSU/E1411**, "Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB  $\rightarrow$  R); Arm B = Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation (RBV  $\rightarrow$  R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB  $\rightarrow$  LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV  $\rightarrow$  LR)." Dr. Till. Activated 6/15/12. Closed: 9/9/16.

**CTSU/E1609**, "A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon  $\alpha$ -2b for Resected High-Risk Melanoma." Dr. Flaherty. Activated: 5/25/11. Closed: 7/26/16.

**CTSU/E1912**, "A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. O'Brien. Activated 2/15/14. Closed: 6/9/16.

**CTSU/E1A11**, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Dr. Zonder. Activated: 12/2/13.

**CTSU/E2810**, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. Pal. Activated: 8/8/12. Closed 7/25/17.

**CTSU/E2906**, "Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age  $\geq 60$  Years)." Dr. Godwin. Activated: 12/28/10. Temporarily closed: 2/23/15.

# Symptom Control & Quality of Life Committee

**CTSU/E3A06**, "Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma." Drs. Dhodapkar and Shaughnessy. Activated: 10/5/10. Closed: 7/14/17.

**CTSU/EA6134**, "A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma." Dr. Chmielowski. Activated: 7/13/15.

**CTSU/N1048**, "A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." Dr. Eng. Activated: 1/13/12.

**CTSU/N107C**, "A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease." Dr. Gaspar. Activated: 7/8/11. Closed to accrual 12/18/15.

**CTSU/R0848**, "A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma." Dr. Philip. Activated: 12/15/09.

**CTSU/R1010**, "A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma." Dr. Leichman. Activated: 12/30/10. Closed 11/10/15.

## Committee Process

Sign and/or correct the meeting attendance/contact list

## Symptom Control & Quality of Life Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1013	S1200	A221101	A221102
Arkansas, U of	—	—	1	—
CORA NCORP	—	—	—	7
CRC West MI NCORP	—	68	—	—
City of Hope Med Ctr	20	—	—	—
Columbia MU-NCORP	3	29	—	—
Fred Hutchinson CRC	—	11	—	—
Greenville NCORP	—	15	—	—
Gulf South MU-NCORP	12	—	—	—
Heartland NCORP	61	—	—	—
Irvine, U of CA	—	—	7	—
Kaiser Perm NCORP	—	56	—	—
Kansas City NCORP	1	—	—	—
Kansas, U of	—	—	1	—
Kentucky, U of	—	—	1	—
Lahey Hosp & Med Ctr	—	10	—	—
Loma Linda Univ	1	—	1	—
Northwest NCORP	—	—	1	—
Oregon Hlth Sci Univ	—	9	—	—
PCRC NCORP	—	20	—	1
Providence Hosp	—	—	2	—
So Calif, U of	26	5	—	—
Southeast COR NCORP	5	—	—	—
Sutter Cancer RC	—	—	1	2
Upstate Carolina	—	—	1	—
Utah, U of	—	3	—	—
Wayne State Univ	3	—	—	—
Wichita NCORP	14	—	—	—
<b>Total</b>	<b>146</b>	<b>226</b>	<b>16</b>	<b>10</b>

## SWOG FACT

SWOG conducts many large trials such as the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a prostate cancer prevention study that enrolled more than 35,000 men. But the group also leads groundbreaking Phase I and Phase II studies to test new targeted therapies, and biospecimen studies that make use of the latest discoveries in cancer genetics.



# Early Therapeutics & Rare Cancers Committee

## Leadership

Chair: ..... Razelle Kurzrock, M.D.  
 Vice-Chair: ..... Young Kwang Chae, M.D., M.P.M.H., M.B.A.  
 Executive Officer: ..... Christopher W. Ryan, M.D.  
 Statisticians: ..... Megan Othus, Ph.D.  
 ..... Melissa Plets, M.S.  
 ..... Edward Mayerson, M.S.

## Designates

Data Coordinators: ..... Laura Kingsbury, M.R.T.  
 ..... Christine McLeod  
 Oncology Research Professionals:  
 CRA: ..... Corrine Turrell, C.C.R.P.  
 Nurse: ..... TBD  
 Pharmaceutical Science: ..... Siu-Fun Wong, Pharm.D.  
 Patient Advocate: ..... Marcia K. Horn, J.D.  
 Protocol Coordinator: ..... TBD

## Early Therapeutics Liaisons

Breast Committee Liaison: ..... George Somlo, M.D.  
 Genitourinary Committee Liaison: ..... Neeraj Agarwal, M.D.  
 Imaging: ..... Oliver Press, M.D.  
 Lung Committee Liaison: ..... Shirish M. Gadgil, M.D.  
 Lymphoma Committee Liaison: ..... Daruka Mahadevan, M.D., Ph.D.  
 Melanoma Committee Liaison: ..... Jeffrey A. Sosman, M.D.  
 Myeloma Committee Liaison: ..... Frits van Rhee, M.D., Ph.D.

## Time/Location

Thursday, October 12, 2017 10:00 a.m. - 12:15 p.m.  
 Regency C, Ballroom Level, West Tower

## Introduction

**10:00 a.m. - 10:05 a.m.:** Razelle Kurzrock, M.D., Senior Deputy Center Director, Director, Center for Personalized Cancer Therapy, Chair, Early Therapeutics and Rare Cancer Committee (SWOG), UCSD Moores Comprehensive Cancer Center, San Diego, CA

## Presentations

**10:05 a.m. – 10:20 a.m.:** "S1716: A Phase II Study of Brentuximab Vedotin (BV) in CD30+ Systemic Mastocytosis and CMML." Uma Borate, M.D., MS, Assistant Professor of Medicine, Oregon Health & Science University, Knight Cancer Institute

**10:20 a.m. – 10:40 a.m.:** "S1717: Randomized Phase III trial of the CancerTYPE ID test in the evaluation of patients with cancer of unknown primary (CUP)." Sarah Yentz, M.D., Hematology-Oncology Fellow; Laurence Baker, D.O., Professor of Medicine; Former SWOG Chair, University of Michigan Comprehensive Cancer Center

**10:40a.m. – 11:00a.m.:** "Rare Cancer Fellowship, Hope Foundation July 1, 2017-June 30, 2017, Opportunities and Challenges." Victor M. Villalobos, M.D., Ph.D., Assistant Professor of Medicine, Director, Sarcoma Medical Oncology, Director, Target-based Therapeutics Team (T3), University of Colorado Denver, Anschutz Medical Campus

**11:00 a.m. – 11:15 a.m.:** "S1720: Efficacy and Safety of Laparoscopic Lymphadenectomy vs. PET/CT as a Classificatory Method for the Treatment of Locally Advanced Cervical Cancer, A Phase III Randomized Clinical Trial." Jesus Antonio Acosta Penaloza, M.D., Co-Director, Instituto Nacional de Cancerologia, Subdirección General de Atención Médica y Docencia, Instituto Nacional de Cancerología, Bogota, Colombia

**11:15 a.m. – 11:45 a.m.:** "Liquid biopsies in Precision Medicine," Filip Janku, MD, Associate Professor, Associate Professor, Investigational Cancer Therapeutics, (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center

**11:45 a.m. – 12:05 p.m.:** "Wrap-up Discussion of Dual Anti-CTLA-4 and Anti-PD-1 blockage in Rare Tumors (DART)," Sandip Patel, M.D., Assistant Professor, UCSD Moores Cancer Center and Young K. Chae, M.D., MPH, Assistant Professor, Co-Director, Experimental Therapeutics Program, Northwestern University

**12:05 p.m. – 12:15 p.m.:** Wrap Up and Open Discussion. Razelle Kurzrock, M.D., Senior Deputy Center Director, Director, Center for Personalized Cancer Therapy, Chair, Early Therapeutics and Rare Cancer Committee (SWOG), UCSD Moores Comprehensive Cancer Center, San Diego, CA

# Early Therapeutics & Rare Cancers Committee

## Active Studies

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. P. Patel, Y. Chae, F. Giles, and R. Kurzrock. Activated: 1/13/17.

**CTS/A071102** "A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation." Dr. D.E. Piccioni. Activated by Alliance 12/15/2014. Activated by SWOG: 4/1/2015. Temporarily closed: 10/21/16.

**CTS/A071401** "Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/ NF2 Mutations." Dr. D.E. Piccioni. Activated by Alliance 8/28/2015. Activated by SWOG: 1/1/2016.

**CTS/ARST1321**, "Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)." Dr. V.M. Villalobos. Activated by COG 1/27/2014. Activated by SWOG: 3/15/2016.

**CTS/EAY131** "Molecular Analysis for Therapy Choice (MATCH)." Dr. V.M. Villalobos. Activated: 8/12/2015.

## Proposed Studies

**S1618**, "A Phase II Study of a selective JAK1 Inhibitor (INCB9110) in Subjects with Advanced Sarcomas." Dr. V.M. Villalobos.

**S1716**, "A Phase I/II study of Brentuximab Vedotin in CD30 + Systemic Mastocytosis and CMML." Drs. U. Borate and A. Gerdts.

**S1717**, "Randomized Phase III trial of the CancerTYPE ID test in the evaluation of patients with cancer of unknown primary (CUP)." Drs. S. Yentz and L. Baker.

**S1720**, "Efficacy and Safety of Laparoscopic Extraperitoneal Para-aortic Lymphadenectomy vs. PET/CT as a Classificatory Method for the Treatment of Locally Advanced Cervical Cancer, a Phase III Randomized Clinical Trial." Dr. J. Acosta.

## Early Therapeutics & Rare Cancers Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1609	A071102	A071401	ARST1321	EAY131
Arkansas, U of	—	—	—	—	3
Baptist MU-NCORP	2	—	—	—	—
Baylor College	—	2	—	—	—
Brooke Army Med Ctr	—	2	—	—	—
CORA NCORP	1	1	1	—	1
Carle CC NCORP	2	—	—	—	—
Cedars-Sinai Med Ctr	1	—	—	—	3
City of Hope Med Ctr	—	—	—	—	3
Cleveland Clinic OH	—	—	—	—	4
Colorado, U of	—	2	1	—	9
Columbus NCORP	1	—	—	—	—
Davis, U of CA	5	—	—	—	5
Dayton NCORP	1	—	—	—	1
Fred Hutchinson CRC	—	—	—	—	2
Hawaii MU-NCORP	—	—	—	—	1
Heartland NCORP	4	—	—	—	1
Henry Ford Hosp	2	—	—	—	9
Irvine, U of CA	—	1	1	—	5
Kaiser Perm NCORP	7	3	—	—	5
Kansas City NCORP	—	—	—	—	1
Kansas, U of	2	—	—	1	4
Kentucky, U of	—	—	—	—	8
Lahey Hosp & Med Ctr	—	3	—	—	—
Loma Linda Univ	—	—	—	—	1
MD Anderson CC	1	—	—	—	—
Methodist Hospital	—	—	—	—	1
Michigan CRC NCORP	7	—	—	—	—
Michigan, U of	1	—	—	—	6
Mississippi, Univ of	—	1	—	—	—
Montana NCORP	4	—	—	—	—
Nevada CRF NCORP	2	—	—	—	—
New Mexico MU-NCORP	4	—	—	—	—
Northwest NCORP	2	—	—	—	—
Northwestern Univ	—	1	—	1	—
Ozarks NCORP	—	2	—	—	—
PCRC NCORP	3	3	—	—	—
Providence Hosp	1	—	—	—	1
Rochester, Univ of	—	8	—	—	—
San Antonio, U of TX	1	—	—	2	3
San Diego, U of CA	2	7	2	—	—
Southeast COR NCORP	4	—	—	—	6
Sutter Cancer RC	1	—	—	—	4
Tulane University	—	—	—	—	1
Yale University	—	1	—	—	7
Alliance	23	—	—	—	—
ECOG-ACRIN	9	—	—	—	—
NRG	20	—	—	—	—
<b>Total</b>	<b>113</b>	<b>37</b>	<b>5</b>	<b>4</b>	<b>95</b>

# Gastrointestinal Committee

## Leadership

Chair: .....Howard S. Hochster, M.D.  
 Vice-Chair: .....Heinz-Josef Lenz, M.D.  
 Executive Officer: .....Christopher W. Ryan, M.D.  
 Statisticians: .....Katherine A. Guthrie, Ph.D.  
 .....Shannon McDonough, M.S.

## Scientific Leadership

Gastroesophageal: .....Syma Iqbal, M.D.  
 .....Lawrence P. Leichman, M.D.  
 .....Scott A. Hundahl, M.D. (Surgical representative)  
 Pancreatic: .....Philip A. Philip, M.D., Ph.D.  
 .....Andrew M. Lowy, M.D. (Surgical representative)  
 Hepatobiliary: .....Anthony B. El-Khoueiry, M.D.  
 .....Milind Javle, M.D.  
 .....Syed Ahmad, M.D. (Surgical representative)  
 Colon: .....Philip J. Gold, M.D.  
 .....Wells A. Messersmith, M.D.  
 .....Kevin G. Billingsley, M.D. (Surgical representative)  
 Rectal: .....Lisa A. Kachnic, M.D.  
 .....Cathy Eng, M.D.  
 Translational Medicine: .....Heinz-Josef Lenz, M.D.  
 .....Christopher H. Lieu, M.D.  
 Drug Development: .....Ramesh Ramanathan, M.D.  
 .....Sunil Sharma, M.D.  
 Imaging: .....Anthony F. Shields, M.D., Ph.D.  
 .....David Shin-Kuo Lu, M.D.  
 Radiation Oncology: .....Lisa A. Kachnic, M.D.

## Designates

Cancer Control Liaison: .....Jason A. Zell, D.O.  
 Data Coordinators: .....Christine McLeod  
 .....Jacqueline Scurlock  
 .....Brian Zeller  
 Oncology Research Professionals:  
 CRA: .....Sandy Annis, C.C.R.P.  
 Nurses: .....Rita Kaul, R.N., B.S.N.  
 .....Valerie A. Parks, R.N.  
 Patient Advocate (Pancreatic): .....Carole Seigel, M.B.A.  
 Patient Advocate (Colon): .....Florence Kurttila, M.S.  
 Pharmaceutical Science: .....Linda Lee-Gabel, Pharm.D.  
 .....Manj Randhawa, Pharm.D.  
 Protocol Coordinator: .....Danae Campos

## Time/Location

Friday, October 13, 2017 4:30 p.m. -6:30 p.m.  
 Crystal B, Lobby Level, West Tower

Introduction. Howard Hochster, M.D., Yale University.

"Treatment resistance to anti-EGFR therapy and ctDNA." Scott Kopetz, M.D., Ph.D., MD Anderson Cancer Center.

Presentation of S1417, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Veena Shankaran, M.D., Fred Hutchinson Cancer Research Center.

## Gastroesophageal

No studies

## Pancreatic

## Active Studies

**S1505**, "A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma." Dr. Sohal. Activated: 10/12/15.

**S1513**, "Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer." Dr. Chiorean. Activated: 9/1/16.

**CTSU/RTOG 0848**, "A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma." Dr. Philip. Activated: 12/15/09.

**CTSU/A021501**, "Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas." Dr. Lieu. Activated: 12/1/16

**EA2142**, "Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas". Activated 11/06/2015.

## Proposed Studies

"A Phase II Study of CCR2 Inhibition testing Folfirinox in Combination with PF-04136309 vs Folfirinox Alone in Locally Advanced Pancreatic Cancer." Dr. Noel.

## Closed Studies

**S1313**, "A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma." Dr. Ramanathan. Activated: 1/15/14. Closed: 7/1/17.



# Gastrointestinal Committee

## Hepatobiliary

### Active Studies

**CTSU/RTOG-1112**, "Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma." Activated: 4/24/13.

## Colon

### Active Studies

**S0820**, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III." Dr. Zell. Activated: 3/1/13.

**S1417CD**, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. Shankaran. Activated: 4/15/16.

**S1415CD**, "A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia – Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)." Drs. Ramsey and Hershman. Activated: 10/7/16.

### Proposed Studies

**S1613**, "A Randomized Phase II study of Trastuzumab and Pertuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in HER2 Amplified Irinotecan-refractory Metastatic Colorectal Cancer (mCRC)." Dr. Raghav.

## Rectal

### Active Studies

**CTSU/N1048**, "A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." Dr. Eng. Activated: 1/13/12.

**CTSU/EA2133**, "InterAACT – An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease." Dr. Morris. Activated: 2/15/16.

**CTSU/NRG-G1002**, "A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer." Dr. Kachnic. Activated: 10/12/2016.

## Other

### Active Studies

**S1316**, "Prospective Comparative Effectiveness Trial For Malignant Bowel Obstruction." Dr. Krouse. Activated: 3/9/15.

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Dr. Patel. Activated: 1/13/17.

**EAY131**, "NCI-MATCH: Molecular Analysis for Therapy Choice." Dr. Villalobos. Activated: 8/12/15.

### Closed

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13 Closed: 2/15/17.

## Correlative Studies

**S9008A**, "Trial of Adjuvant Chemoradiation after Gastric Resection Adenocarcinoma, Phase III." Dr. Shridhar.

**S-C80405-A**, "Analysis of EGFR and ERCC1 Markers and Progression-Free Survival in Patients with Advanced Colorectal Cancer Enrolled on C80405." Drs. Shields and Lenz.

## Other Proposed Studies

A Randomized Phase II/III Study of Gemcitabine and Cisplatin followed by Capecitabine/Radiation versus Gemcitabine and Cisplatin Alone. Dr. El-Khoueiry.



### SWOG FACT

An average of 5,000 cancer patients and healthy participants enroll each year in SWOG studies, and approximately 20,000 more are involved in ongoing clinical trials.

## Gastrointestinal Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1313	S1406	S1505	S1513	A021202	A021501	E2211	E7208	E7208	EA2142	N1048	NRGGI002	R0848	NRGGI002
Arizona MC, U of	4	—	—	—	—	—	—	—	—	—	4	—	—	—
Baptist MU-NCORP	—	1	—	—	—	—	—	—	—	—	—	—	—	—
Baylor College	—	—	—	—	—	—	—	—	—	—	14	—	—	—
Baylor Univ Med Ctr	—	—	—	—	2	—	—	—	—	—	—	—	—	—
Boston Medical Ctr	—	—	—	—	—	—	1	—	—	—	2	—	—	—
CORA NCORP	—	—	—	—	—	—	—	—	—	—	2	—	—	1
CRC West MI NCORP	—	1	—	2	—	—	—	1	—	—	2	—	—	1
Carle CC NCORP	—	—	—	1	—	—	—	—	—	—	—	—	—	—
Cedars-Sinai Med Ctr	—	—	2	1	—	—	13	—	—	—	—	—	—	—
Cincinnati MC, U of	—	—	—	—	4	—	13	—	—	—	—	—	—	—
City of Hope Med Ctr	—	—	2	—	—	—	3	—	—	—	—	—	—	—
Cleveland Clinic OH	3	3	—	2	—	—	—	—	—	—	—	—	—	—
Colorado, U of	—	4	2	—	—	—	2	—	—	—	1	—	—	—
Columbia MU-NCORP	—	4	—	1	1	—	—	—	—	—	1	—	—	—
Columbia University	—	—	—	1	—	—	—	—	—	—	—	—	2	—
Columbus NCORP	—	—	—	—	—	—	—	—	—	—	—	—	2	—
Davis, U of CA	—	2	—	—	—	—	—	—	—	—	2	—	1	—
Dayton NCORP	1	—	—	—	—	—	—	—	—	—	2	—	—	—
Essentia Hlth NCORP	—	—	1	1	—	—	—	—	—	—	2	1	—	—
Fred Hutchinson CRC	—	1	—	—	—	—	—	—	—	—	14	—	—	—
Greenville NCORP	14	—	—	—	—	—	—	—	—	—	14	—	—	—
Gulf South MU-NCORP	—	1	2	—	—	—	2	—	—	—	—	—	1	—
H Lee Moffitt CC	—	2	—	1	—	—	—	—	—	—	—	—	—	—
Hawaii MU-NCORP	—	—	—	—	22	—	10	—	—	—	—	—	—	—
Heartland NCORP	—	—	—	—	—	—	—	—	—	—	—	—	1	—
Irvine, U of CA	8	2	5	3	—	—	—	—	—	—	—	—	—	—
Kaiser Perm NCORP	7	1	—	—	—	1	—	—	—	—	8	—	6	—
Kansas City NCORP	7	—	—	—	—	—	1	—	—	—	—	—	—	—
Kansas, U of	—	3	—	—	1	—	5	—	1	—	—	—	1	—
Kentucky, U of	—	—	2	—	—	—	2	—	—	—	—	—	—	—
Lahey Hosp & Med Ctr	—	—	—	—	—	—	1	—	—	—	11	—	—	—



# Since 1956,

we've conducted more than  
1,400 cancer clinical trials.

Our research has made life longer,  
or better, for thousands of people.

We expanded our patient advocate  
committee to 19 members, making  
it one of the largest, and the most  
experienced, groups in the NCTN.

## Gastrointestinal Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1313	S1406	S1505	S1513	A021202	A021501	E2211	E7208	E7208	EA2142	N1048	NRGGI002	R0848	NRGGI002
Loyola University	—	—	—	—	—	—	1	—	—	—	—	—	4	—
MD Anderson CC	—	18	—	—	—	—	—	—	—	—	—	—	—	—
MUSC MU-NCORP	5	—	3	1	—	—	—	—	—	—	—	—	—	—
Methodist Hospital	—	—	—	—	1	—	—	—	—	—	10	—	—	—
Michigan CRC NCORP	—	—	—	2	—	—	—	—	—	—	—	—	—	—
Michigan, U of	—	2	5	—	—	2	1	1	—	2	4	—	—	—
New Mexico MU-NCORP	—	—	—	3	—	—	—	—	—	—	—	—	—	—
Northwest NCORP	—	1	—	—	—	—	—	—	—	—	—	—	3	—
Northwestern Univ	—	—	—	—	—	—	—	1	—	—	1	—	—	—
Orange Reg Med Ctr	—	—	—	—	—	—	—	—	—	—	—	1	—	—
Oregon Hlth Sci Univ	—	—	1	—	—	—	—	—	—	—	—	—	—	—
Ozarks NCORP	—	1	—	—	—	—	—	—	—	—	1	—	—	—
PCRC NCORP	6	1	4	—	—	—	—	—	—	—	1	—	—	—
Providence Hosp	—	1	—	—	—	—	—	1	—	—	—	—	—	—
Rochester, Univ of	—	—	3	6	1	—	4	—	—	—	19	—	—	—
San Antonio, U of TX	—	1	—	—	2	—	—	—	—	—	—	—	—	—
San Diego, U of CA	—	—	4	—	—	—	—	—	—	—	4	—	—	—
Scott & White Mem	—	—	—	—	—	—	—	1	—	—	1	—	—	—
So Calif, U of	6	1	—	—	—	—	2	6	—	—	—	—	—	—
Southeast COR NCORP	5	3	2	2	—	—	—	—	—	—	—	—	—	—
Sutter Cancer RC	9	1	—	—	—	—	—	—	—	—	—	—	—	—
Utah, U of	—	—	—	6	—	—	—	—	—	—	3	—	—	—
Wayne State Univ	11	2	—	—	—	—	—	1	—	—	—	—	—	—
Wichita NCORP	—	—	—	—	—	—	—	—	—	—	—	—	1	—
Wisconsin NCORP	—	—	3	1	—	—	—	—	—	—	—	—	—	—
Yale University	40	5	—	2	—	—	2	11	—	—	—	—	—	—
Alliance	—	19	9	9	—	—	—	—	—	—	—	—	—	—
ECOG-ACRIN	—	10	14	6	—	—	—	—	—	—	—	—	—	—
NRG	—	7	13	10	—	—	—	—	—	—	—	—	—	—
<b>Total</b>	<b>126</b>	<b>106</b>	<b>81</b>	<b>66</b>	<b>35</b>	<b>3</b>	<b>55</b>	<b>23</b>	<b>1</b>	<b>2</b>	<b>124</b>	<b>2</b>	<b>20</b>	<b>1</b>

We registered over 1,000 patients  
to Lung-MAP,  
our precision medicine trial

# Thanks, team!





# Genitourinary Committee

## Leadership

Chair: ..... Ian M. Thompson, Jr., M.D.  
 Vice-Chair: ..... Nicholas J. Vogelzang, M.D.  
 Executive Officer: ..... Christopher W. Ryan, M.D.  
 Statisticians: ..... Cathy M. Tangen, Dr.P.H.  
 ..... Melissa Plets, M.S.  
 ..... Eddie Mayerson, M.S.

## Scientific Leadership

Translational Medicine: ..... David J. McConkey, Ph.D.  
 ..... Joshua J. Meeks, M.D., Ph.D. (Bladder)  
 ..... Amir Goldkorn, M.D. (Prostate)  
 ..... Brian Shuch, M.D. (Renal)  
 Radiation Oncology: ..... David Raben, M.D.  
 Imaging: ..... Daniel W. Lin, M.D.  
 ..... John D. Hazle, Ph.D.  
 Pathology: ..... M. Scott Lucia, M.D.  
 Liaison to the SPORES: ..... Colin P.N. Dinney, M.D.  
 Early Therapeutics: ..... Neeraj Agarwal, M.D.  
 Bladder Organ Site Chairs: ..... Seth P. Lerner, M.D. (Localized)  
 ..... Daniel P. Petrylak, M.D. (Advanced)  
 Prostate Organ Site Chairs: ..... Daniel W. Lin, M.D. (Localized)  
 ..... David I. Quinn, M.D., Ph.D. (Advanced)  
 Renal Organ Site Chairs: ..... Edward M. Messing, M.D. (Localized)  
 ..... Primo N. Lara, Jr., M.D. (Advanced)

## Designates

Cancer Control: ..... Peter J. Van Veldhuizen, Jr., M.D.  
 Data Coordinators: ..... Diana Heaney  
 ..... Sean O'Bryan  
 ..... Joseph Sanchez  
 Oncology Research Professionals:  
 CRA: ..... Theresa Witcher, R.N.  
 Nurses: ..... Deborah A. Shaw, R.N.  
 ..... Cheryl Kefauver, R.N.  
 Patient Advocates: ..... Rick Bangs, M.B.A. (Bladder)  
 ..... Tony Crispino (Prostate)  
 ..... Margaret "Peggy" Zuckerman, M.Ed. (Renal)  
 Pharmaceutical Science: ..... Joyce Lee, Pharm.D.  
 ..... Rivka Siden, Pharm.D.  
 Protocol Coordinator: ..... Nicki Trevino

## Time/Location

Saturday, October 14, 2017 9:30 a.m. - 12:30 p.m.  
 Regency A, Ballroom Level, West Tower

**Introductions and Announcements** - Ian M. Thompson, Jr., M.D.

**Translational Medicine in the GU Committee** - David J. McConkey, Ph.D. and Christopher W. Ryan, M.D.

## Cancer Control

Liaison: Dr. Peter J. Van Veldhuizen

## Active Studies

**S1316**, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Drs. Krouse, Badgwell, and Sun. Activated: 3/9/15.

## Closed Studies

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13. Closed: 2/15/17.

## Renal

Organ Site Chairs: Drs. Primo N. Lara, Jr. (Advanced) and Edward M. Messing (Local)

## Active Studies

**S1500**, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. Pal, Lara, and Shuch. Activated: 4/5/16.

**CTSU/EA8143**, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. Lara and Shuch. Activated: 2/2/17.

## Closed Studies

**S0931**, "EVEREST: EVerolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. Ryan, Heath, Lara, Palapattu, and Mack. Activated: 4/1/11. Closed: 9/15/16.

## Prostate

Organ Site Chairs: Drs. David I. Quinn (Advanced) and Daniel W. Lin (Local)

## Active Studies

**CTSU/NRG-GU003**, "A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)." Dr. David Raben. Activated: 7/28/2017.

# Genitourinary Committee

**CTSU/NRG-GU002**, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel." Dr. David Raben. Activated: 12/30/2016.

**CTSU/A031102**, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. Quinn. Activated: 7/1/15.

**RTOG-0924**, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. David Marshall. Activated: 7/7/2011.

## Closed Studies

**S1216**, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. Agarwal, Goldkorn, Gupta, Hussain, and Lara; T. Crispino. Activated: 3/1/13. Closed 7/15/2017.

## SWOG Champions needed: EA8173

### Bladder

Organ Site Chairs: Drs. Daniel P. Petrylak (Advanced) and Seth P. Lerner (Local)

## Active Studies

**S1602**, "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Dr. Svatek. Activated: 2/7/17.

**S1605**, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. Black and Singh. Activated: 2/7/17.

**S1314**, "A Randomized Phase II Study of CO-eXpression Extrapolation (COXEN) Directed Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer." Drs. Flaig, Alva, Daneshmand, Goldkorn, Lerner, Lucia, McConkey, and Theodorescu. Activated: 7/9/14.

**CTSU/EA8141**, "A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma." Drs. Godoy and Alva. Activated 4/10/15.

## Closed Studies

**S1011**, "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. Lerner, Alva, Koppie, LaRosa, Pal, and Svatek; R. Bangs. Activated: 8/1/11. Closed: 2/15/2017.

## Diverse Studies of Interest

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, Kurzrock, Giles. Activated: 1/13/17.

**CTSU/EAY 131**, "Molecular Analysis for Therapy Choice (MATCH)." Dr. Villalobos. Activated: 8/12/15.

## SWOG FACT

Among SWOG's member sites are 28 National Cancer Institute-designated cancer centers, as well as many leading university medical centers, private oncology practices, community hospitals, and community-based physician cooperatives.

Among the roughly 80 SWOG studies now underway are many testing new targeted therapies that show promise in blocking cancer-promoting genes and cellular processes while sparing healthy cells. Others break new ground as they test ways to tailor cancer treatment to a patient's individual needs and genetic makeup. Still others examine ways to prevent cancer.



# Genitourinary Committee

## Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S0931	S1011	S1216	S1314	S1500	S1602	S1605	A031102	A031201	E2810	EA8141	R0815	R0924
Arizona MC,	13	—	10	3	—	—	—	—	10	—	—	—	—
Arkansas, U of	10	—	6	—	—	—	—	—	4	—	—	—	—
Atlanta Reg CCOP	7	—	—	—	—	—	—	—	—	—	—	—	—
BC Cancer Agency	—	22	—	—	—	—	—	—	—	—	—	—	—
Baptist MU-NCORP	3	—	1	—	—	—	—	—	—	—	—	—	—
Bay Area NCORP	1	—	—	—	—	—	—	—	—	—	—	—	—
Baylor College	21	51	16	3	—	—	—	—	3	—	—	—	—
Beaumont NCORP	8	—	3	—	—	—	—	—	—	—	—	—	—
Birmingham, U of AL	—	—	—	1	—	—	—	—	—	—	1	—	—
Boston MC MBCCOP	1	—	3	—	—	—	—	—	11	—	—	—	—
Boston Medical Ctr	1	—	—	—	—	—	—	—	—	—	—	—	—
Brooke Army Med Ctr	2	—	—	—	—	—	—	—	—	—	—	—	—
CORA NCORP	7	—	2	—	—	—	—	—	3	—	—	1	1
CRC West MI NCORP	15	—	4	—	—	—	—	—	—	—	—	—	—
Carle CC NCORP	—	—	2	—	—	—	—	—	—	—	—	—	—
Cedars-Sinai Med Ctr	13	—	—	—	1	—	—	—	—	—	—	—	—
Cincinnati MC, U of	6	—	1	—	—	—	—	—	3	—	—	—	—
City of Hope Med Ctr	41	—	49	7	11	—	—	—	22	16	—	—	—
Cleveland Clinic OH	—	7	—	10	—	—	—	—	38	—	—	—	—
Colorado, U of	27	3	4	8	—	—	—	—	5	—	5	—	—
Columbia MU-NCORP	6	—	2	—	—	—	—	—	—	1	—	—	—
Columbia University	3	—	—	—	—	—	—	—	—	—	—	—	—
Columbus NCORP	17	—	6	—	—	—	—	—	—	—	—	—	—
Davis, U of CA	13	12	37	3	—	—	—	—	10	—	—	—	—
Dayton NCORP	16	—	9	—	—	—	—	—	—	—	—	—	—
Desert Hospital	—	—	—	—	—	—	—	—	—	—	—	2	5
Fred Hutchinson CRC	2	—	28	—	—	—	—	—	—	—	—	—	—
Galveston, U of TX	1	—	—	—	—	—	—	—	—	—	—	—	—
Georgia NCORP	2	—	2	—	—	—	—	—	1	1	—	—	—
Greenville NCORP	6	—	—	2	—	—	—	—	—	—	—	—	—
Gulf Coast MBCCOP	1	—	—	—	—	—	—	—	—	—	—	—	—
Gulf South MU-NCORP	17	4	2	3	—	7	1	—	—	—	—	—	—
H Lee Moffitt CC	—	2	32	—	—	—	—	—	—	—	—	—	—
Harrison Medical Ctr	—	—	—	—	—	—	—	—	2	—	—	—	—
Hawaii MU-NCORP	13	—	—	—	—	—	—	—	1	—	—	—	—
Heartland NCORP	37	—	38	17	1	1	1	—	3	—	—	2	—
Henry Ford Hosp	8	—	—	—	—	—	—	—	14	1	—	—	—
Irvine, U of CA	8	—	6	—	—	—	—	—	2	—	—	—	—
Kaiser Perm NCORP	14	—	83	—	—	—	—	—	97	—	—	—	—
Kansas City NCORP	7	—	6	—	—	—	—	—	—	—	—	—	—
Kansas, U of	29	—	29	10	—	—	—	—	9	6	1	—	2
Kentucky, U of	—	—	16	—	—	—	—	—	—	—	—	—	—



## Genitourinary Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S0931	S1011	S1216	S1314	S1500	S1602	S1605	A031102	A031201	E2810	EA8141	R0815	R0924
Lahey Hosp & Med Ctr	2	—	3	—	—	—	—	—	—	—	—	—	—
Loma Linda Univ	—	—	13	5	—	—	—	—	3	—	—	—	—
Loyola University	32	15	6	2	—	—	—	—	2	1	—	3	—
MAVERIC	—	—	—	—	—	—	—	—	5	—	—	—	—
MD Anderson CC	—	49	4	1	—	—	—	—	—	—	1	—	—
MUSC MU-NCORP	1	—	12	1	1	—	—	—	—	—	—	1	2
Michigan Army Med Ctr	3	—	2	—	—	—	—	—	—	—	—	—	—
Michigan CRC NCORP	20	—	17	3	1	—	—	—	—	—	—	—	—
Michigan, U of	34	—	17	—	2	3	—	—	—	1	—	—	—
Mississippi, Univ of	3	—	1	—	—	—	—	—	—	—	—	—	—
Montana NCORP	10	—	3	2	—	—	—	—	—	—	—	—	—
Nevada CRF NCORP	11	—	45	9	2	—	—	—	—	—	—	—	—
New Mexico MU-NCORP	2	—	26	—	—	—	—	—	—	—	—	—	—
Northwest NCORP	15	—	4	—	—	—	—	—	—	—	—	—	—
Northwestern Univ	—	—	3	—	—	—	—	—	—	—	—	—	—
Oklahoma, Univ of	6	—	16	5	1	1	1	—	—	—	—	—	—
Orange Reg Med Ctr	1	—	1	—	—	—	—	—	—	—	—	—	—
Oregon Hlth Sci Univ	22	19	21	3	1	—	—	—	—	6	—	—	—
Ozarks NCORP	13	—	5	2	—	—	—	—	—	—	—	—	—
PCRC NCORP	31	—	7	—	—	2	—	—	—	—	—	—	—
Rochester, Univ of	14	1	7	5	—	—	—	—	6	—	—	2	15
San Antonio, U of TX	27	50	3	8	—	1	—	—	—	—	—	—	—
San Diego, U of CA	—	—	6	1	—	—	—	—	—	—	—	—	—
Scott & White CCOP	3	—	—	—	—	—	—	—	—	—	—	—	—
Scott & White Mem	2	—	—	—	—	—	—	—	—	—	—	—	—
So Calif, U of	9	153	34	10	—	—	—	2	11	1	—	1	—
Southeast COR NCORP	32	—	6	1	—	—	—	—	—	1	—	—	—
St Louis CCOP	4	—	—	—	—	—	—	—	—	—	—	—	—
St Louis University	1	—	—	—	—	—	—	—	—	—	—	—	—
Sutter Cancer RC	23	—	5	—	—	—	—	—	1	—	—	—	1
Tennessee, U of	5	—	—	—	—	—	—	—	12	1	—	—	—
Upstate Carolina	1	—	1	—	—	—	—	—	—	—	—	—	—
Utah, U of	25	—	106	5	1	1	—	—	—	12	—	—	—
VAMC Kansas City	—	—	2	—	—	—	—	—	1	—	—	—	21
Wayne State Univ	15	—	—	1	2	—	—	—	6	—	—	1	—
Wichita NCORP	23	—	12	1	1	1	—	—	—	—	—	—	—
Wisconsin NCORP	1	—	2	2	—	—	—	—	—	—	—	—	—
Yale University	6	—	7	1	—	—	—	—	—	—	—	—	—
Alliance	297	105	239	39	5	—	2	—	—	—	—	—	—
CCTG	—	38	—	—	2	—	—	—	—	—	—	—	—
ECOG-ACRIN	396	87	240	18	6	—	—	—	—	—	—	—	—
NRG	78	—	40	16	5	—	1	—	—	—	—	—	—
<b>Total</b>	<b>1,545</b>	<b>618</b>	<b>1,313</b>	<b>208</b>	<b>43</b>	<b>16</b>	<b>6</b>	<b>2</b>	<b>287</b>	<b>48</b>	<b>8</b>	<b>13</b>	<b>48</b>

# Leukemia Committee

## Leadership

Chair: ..... Harry P. Erba, M.D., Ph.D.  
 Vice-Chair: ..... Steven E. Coutre, M.D.  
 Executive Officer: ..... Susan M. O'Brien, M.D.  
 Statisticians: ..... Megan Othus, Ph.D.  
 ..... Anna Moseley, M.S.

## Scientific Leadership

Translational Medicine: ..... Jerald P. Radich, M.D.  
 Pathology: ..... David R. Head, M.D.  
 Cytogenetics Liaison: ..... Diane Roulston, Ph.D.  
 ..... Min Fang, M.D., Ph.D.

## Designates

Data Coordinators: ..... Louise Highleyman  
 ..... Laura Kingsbury, M.R.T.  
 ..... Tracy Maher, C.C.R.P.  
 Oncology Research Professionals:  
 CRA: ..... TBD  
 Nurses: ..... Keisha C. Humphries, R.N., B.S.N.  
 ..... Mary Lynn Rush, R.N., B.S.N.  
 Patient Advocate: ..... Gail Sperling, M.P.H.  
 Pharmaceutical Science: ..... Holly O. Chan, Pharm.D.  
 ..... Mai T. Nguyen, Pharm.D.  
 Protocol Coordinator: ..... Sandi Hita

## Time/Location

Saturday, October 14, 2017 9:30 a.m. - 11:30 a.m.  
 Regency C, Ballroom Level, West Tower

## Introduction

### Leukemia Committee Updates – Dr. Harry Erba

#### AML/MDS Studies

## Active Studies

**CTSU/E2905**, “Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alpha (Procrit®) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia.” Dr. C.A. Schiffer. Activated by ECOG: 1/29/09; Activated by SWOG: 2/15/09.

## Proposed Studies

**S1612**, “A Randomized Phase II/III Trials of “Novel Therapeutic Regimens” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older.” Drs. L. Michaelis and R. Walter.

**S1804**, “Optimization of Gemtuzumab Ozogamicin in Combination with Chemotherapy for Adults with Newly Diagnosed Favorable- or Intermediate-Risk Acute Myeloid Leukemia (AML): A Randomized Phase II Study.” Dr. R. Walter.

## Closed Studies

**S0919**, “A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML).” Drs. A.S. Advani and L.C. Michaelis. Activated: 8/15/09. Closed: 9/15/17

## ALL Studies

## Active Studies

**S1318**, “A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients  $\geq$  65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients  $\geq$  65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL.” Drs. A.S. Advani and K. O'Dwyer. Activated: 1/12/2015.

**S1312**, “A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia).” Drs. A.S. Advani and M. Liedtke. Activated: 4/1/14.

**CTSU/E1910**, “A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.” Dr. M. Liedtke. Activated by ECOG: 12/17/13. Activated by SWOG: 1/15/14.

## Proposed Studies

**S1704**, “A Phase II Trial of PR-104 in Relapsed/Refractory Patients with T-cell Acute Lymphoblastic Leukemia.” Drs. A.S. Advani and W. Stock.

# Leukemia Committee

Ozogamicin for Patients with Relapsed/Refractory CD22+ Acute Lymphoblastic Leukemia (ALL)." Drs. A.S. Advani and C. Yeung.

**A041501**, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab ozogamicin (a conjugated anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 16-39 years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A.S. Advani.

**CTSU/EXXXX**, "A Phase II Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumomab and Allo-HCT for Newly Diagnosed BCR-ABL-positive ALL in Adults." Drs. Kathleen Phelan, Yishai Ofran, and Katarzyna Jamieson.

## CLL Studies

### Active Studies

**CTSU/E1912**, "A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. S. O'Brien. Activated by ECOG: 1/31/14; Activated by SWOG: 2/15/14.

### Closed Studies

**CTSU/A041202**, "A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ( $\geq 65$  Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. S.E. Coutre. Activated by Alliance: 12/9/13; Activated by SWOG: 12/15/13.

### Proposed Studies

**S1718**, "Randomized, Phase III Study of Early Intervention with Ibrutinib or Ibrutinib, Venetoclax, and Obinutuzumab (I-V-O) versus Delayed Therapy with I-V-O in Newly Diagnosed Asymptomatic Patients with High-Risk Chronic Lymphocytic Leukemia (CLL)." Drs. D. Stephens and A. Danilov.

## CML Studies

### Proposed Studies

**S1712**, "A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease." Drs. K. Sweet and J. Radich. (Formerly S1615)

## SWOG: Who we are



**Dr. Veena Shankaran** launched the first financial toxicity trial in the National Clinical Trials Network



**Dr. Manuel Valdivieso** is the SWOG executive officer overseeing international initiatives



## Leukemia Committee


### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S0919	S1312	S1318	A041202	E1910	E1912	E2905	E2906	NHLBIMDS
Arizona MC, U of	—	—	—	3	3	—	—	7	—
Arkansas, U of	—	—	1	1	3	8	—	—	—
Baptist MU-NCORP	—	—	—	1	—	—	—	—	—
Baylor College	5	4	—	—	—	—	—	—	—
Beaumont NCORP	—	—	—	—	—	6	—	—	—
Birmingham, U of AL	3	—	1	—	6	1	—	—	—
Boston Medical Ctr	—	—	—	2	—	—	—	—	—
CORA NCORP	—	—	—	2	—	1	1	—	—
CRC West MI NCORP	—	—	—	—	—	—	—	4	—
Cincinnati MC, U of	—	—	—	—	—	—	—	3	—
City of Hope Med Ctr	—	13	4	7	—	—	—	—	—
Cleveland Clinic OH	23	10	4	7	4	—	—	—	1
Colorado, U of	6	—	—	1	—	—	2	—	—
Columbia MU-NCORP	—	—	—	—	—	—	1	3	—
Columbia University	—	—	—	—	—	—	1	—	—
Columbus NCORP	—	—	—	1	—	—	—	—	—
Davis, U of CA	—	—	—	—	—	—	5	—	—
Dayton NCORP	—	—	—	—	—	—	—	5	—
Fred Hutchinson CRC	—	—	—	—	—	8	—	—	—
Greenville NCORP	—	—	1	—	1	1	6	—	—
Gulf South MU-NCORP	1	—	—	—	—	—	—	—	—
H Lee Moffitt CC	11	—	—	—	—	—	29	—	1
Harrington CC	—	—	—	—	—	1	—	—	—
Heartland NCORP	—	—	1	—	—	—	—	—	—
Henry Ford Hosp	—	—	—	—	2	—	1	—	—
Irvine, U of CA	—	—	3	2	4	1	—	—	—
Kaiser Perm NCORP	—	—	—	31	—	29	7	—	1
Kansas City NCORP	—	—	—	—	—	1	2	—	—
Kansas, U of	—	—	—	6	8	1	1	—	—
Kentucky, U of	—	—	—	—	—	—	—	7	—
Lahey Hosp & Med Ctr	—	—	—	2	—	2	—	—	—

## Our History

Dr. Grant Taylor,  
first SWOG  
group chair



Founded in 1956 by the National Cancer Institute, we are part of the NCI's National Clinical Trials Network, the largest and oldest publicly funded cancer research network in the United States. We are also part of NCI's Community Oncology Research Program, which connects us to community hospitals and clinics across the nation – and the diverse populations they serve.



Our members include more than 12,000 research professionals working in 47 states and six other countries, and our bio-repository holds more than 800,000 specimens accessible to fellow researchers around the world.

## Leukemia Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S0919	S1312	S1318	A041202	E1910	E1912	E2905	E2906	NHLBIMDS
Loma Linda Univ	—	—	1	—	—	—	—	—	—
Loyola University	4	—	—	—	—	3	—	9	—
MAVERIC	—	—	—	1	—	—	—	—	—
Michigan, U of	—	—	2	—	—	—	—	—	—
Mississippi, Univ of	1	—	—	—	—	—	—	1	—
Montana NCORP	—	—	—	—	—	3	4	—	—
New Mexico MU-NCORP	5	—	1	—	—	—	—	1	—
Northwest NCORP	—	—	—	—	5	1	—	—	—
Northwestern Univ	—	—	—	2	1	2	—	—	—
Orange Reg Med Ctr	—	—	—	3	—	1	—	—	—
Oregon Hlth Sci Univ	6	—	—	—	—	—	—	—	2
Ozarks NCORP	—	—	—	—	—	1	—	—	—
PCRC NCORP	2	—	—	1	—	1	1	—	—
Providence Hosp	—	—	—	—	—	1	2	—	—
Rochester, Univ of	15	7	1	10	4	24	3	27	—
San Antonio, U of TX	—	—	—	1	—	2	3	—	—
San Diego, U of CA	—	—	1	—	3	—	—	—	—
So Calif, U of	—	—	3	—	—	—	—	—	—
Southeast COR NCORP	—	—	—	—	—	—	1	—	—
Stanford University	24	2	—	6	6	21	—	—	—
Sutter Cancer RC	—	—	—	1	—	2	—	—	—
Tulane Univ MBCCOP	1	—	—	—	—	—	—	—	—
Tulane University	2	—	—	—	—	—	—	—	—
Upstate Carolina	—	—	—	—	—	—	—	3	—
Wayne State Univ	—	—	—	2	1	3	5	—	—
Wichita NCORP	6	—	1	—	—	—	—	—	—
Yale University	—	—	—	6	13	5	6	5	—
Alliance	—	—	13	—	—	—	—	—	—
ECOG-ACRIN	—	—	6	—	—	—	—	—	—
<b>Total</b>	<b>115</b>	<b>36</b>	<b>44</b>	<b>99</b>	<b>64</b>	<b>130</b>	<b>81</b>	<b>75</b>	<b>4</b>

## SWOG Offices

1. The Hope Foundation, Ann Arbor, MI
2. SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA
3. SWOG Group Chair's Office, Knight Cancer Institute at Oregon Health & Science University, Portland, OR
4. SWOG Operations, San Antonio, TX



## Our 2016 Highlights

- We tipped our member scales at over **1,000 sites** across the U.S. and six other countries
- We registered over **1,000 patients** to Lung-MAP, our precision medicine trial
- We trained about **300 clinical trial professionals** in Mexico City, Peru, and Columbia under our SWOG Latin America Initiative
- We applied for, and received, over **\$2.4 million** in National Institutes of Health supplemental funding for our trials

# Lung Committee

## Leadership

Chair: .....Karen Kelly, M.D.  
 Vice-Chair: .....Roy S. Herbst, M.D., Ph.D.  
 Executive Officer: .....Julie R. Gralow, M.D.  
 Statisticians: .....Mary Redman, Ph.D.  
 .....Jieling Miao, M.S.  
 .....James Moon, M.S.  
 .....Katherine Griffin, M.S.

## Scientific Leadership

Translational Medicine: .....Philip C. Mack, Ph.D.  
 .....Fred R. Hirsch, M.D., Ph.D.  
 Radiation Oncology: .....Roy H. Decker, M.D., Ph.D.  
 Surgery: .....Wayne L. Hofstetter, M.D.  
 Imaging: .....Anthony F. Shields, M.D., Ph.D.  
 .....Friedrich D. Knollmann, M.D., Ph.D.  
 Pathology: .....Ignacio I. Wistuba, M.D.  
 Early Therapeutics: .....Shirish M. Gadgeel, M.D.

## Designates

Cancer Control Liaison: .....Gary E. Goodman, M.D.  
 Community Affiliate: .....Paul J. Hesketh, M.D.  
 Data Coordinators: .....Krystle Pagarigan  
 .....Louise Highleyman  
 .....Larry Kaye  
 .....Sarah Basse  
 Oncology Research Professionals:  
 CRAs: .....Courtney L. Williamson  
 .....Ginny M. Keeling, M.S.  
 Nurses: .....Kimberly M. Belzer, M.S., P.A.C  
 .....Rosalie Zablocki, R.N.  
 Patient Advocate: .....Judy Johnson, M.B.A.  
 Pharmaceutical Science: .....Joyce Lee, Pharm.D.  
 .....Linda Lee-Gabel, Pharm.D.  
 Protocol Coordinator: .....Dawne Wenzel, M.A., M.S.  
 .....Crystal Miwa (Lung-MAP Protocol)

## Time/Location

Thursday, October 12, 2017 4:45 p.m. - 7:45 p.m.  
 Regency D, Ballroom Level, West Tower

**4:45 p.m.:** Opening Remarks and General Update – Dr. Kelly

Patient Advocate Judy Johnson

**5:00 p.m.:** Thoracic Surgery Session – Dr. Hofstetter

- Scientific Presentation - Local treatment for oligometastatic disease. Daniel Gomez, M.D., Associate Professor, Department

of Radiation Oncology, MD Anderson Cancer Center

- Update on Current Trials
- Review of Trials in Development

**5:30 p.m.:** Thoracic Radiation Session – Dr. Decker

- Scientific Presentation - Treatment of Brain Metastasis. Joseph N. Contessa, M.D., Ph.D., Associate Professor of Therapeutic Radiology and of Pharmacology; Director, Central Nervous System Radiotherapy Program, Yale Cancer Center

- Update on Current Trials
- Review of Trials in Development

**6:10 p.m.:** Translational Medicine Session – Dr. Mack

- Update

**6:30 p.m.:** Thoracic Oncology Session

- Scientific Presentations:

ESMO 2017 Lung Cancer Update. Karen Kelly M.D., Professor, UC Davis Comprehensive Cancer Center

Advances in Mesothelioma. Anne S. Tsao, M.D., Professor and Director of the Mesothelioma Program, MD Anderson Cancer Center

**7:00 p.m.:** Mesothelioma

- Update on Current Trials
- Review of Trials in Development

Thymic Carcinoma

- Review of Trials in Development

NSCLC

- Update on Current Trials
- Review of Trials in Development

Small Cell Lung Cancer

- Update on Current Trials
- Review of Trials in Development

## Active Studies

**S1507,** “A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive



# Lung Committee

Disease Following One or Two Prior Systemic Therapies." Drs. Gadgeel, Riess and Mack. Activated: 7/17/16.

**S1403**, "A Randomized Phase II/III Trial of Afatinib Plus Cetuximab versus Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)." Drs. Goldberg, Lilenbaum and Politi. Activated: 3/25/15.

**S1400**, "A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer." Drs. Papadimitrakopoulou, Hirsch, Herbst, Schwartz, Gandara and Mack. Activated: 6/16/14.

**S1400G**, "A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study)." Drs. Owonikoko and Byers. Activated: 2/7/17.

**S1400I**, "A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-study)." Drs. Gettinger and Bazhenova. Activated: 12/18/15.

**S1206 (8811)**, "A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)." Drs. Argiris, Cristea and Chen. Activated: 10/1/12; Phase II open: 7/15/16.

**CTSU/EAY131**, "Molecular Analysis for Therapy Choice (MATCH)." Dr. Villalobos. Activated: 8/12/15.

**CTSU/A151216**, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHE-MIST)." Dr. Gandara. Activated: 8/18/14.

**CTSU/A081105**, "Randomized Study of Erlotinib versus Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Kelly. Activated: 8/18/14.

**CTSU/EA5142**, "Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers." Jamie E. Chافت, M.D. Activated: 5/6/16.

**CTSU/NRGCC003**, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hip-pocampal Avoidance For Small Cell Lung Cancer." Vinai Gondi, MD. Activated on 12/07/2015.

**CTSU/E4512**, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients

with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activated: 8/18/14.

**CTSU/R1306**, "A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer." Drs. Tsao and Daly. Activated: 11/4/13.

**CTSU/CALGB 30610**, "Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide." Drs. Gadgeel and Gaspar. Activated: 3/15/08.

## NCI Approved Concepts

**S1619**, "A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma." Dr. Tsao.

**S1701**, "A Phase II Trial of Carboplatin, Paclitaxel, and Ramucirumab in Patients with Locally Advanced, Metastatic, or Recurrent Thymic Epithelial Tumors (TET) not Amenable to Curative Intent Surgery." Dr. Tsao.

**S1400F**, "A Phase II Study of MEDI4736 Plus Tremelimumab as Therapy for Patients with Previously Treated anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)." Drs. Leighl and Rizvi.

**S1400K**, "A Phase II Study of ABBV-399 in Patients with c-MET Positive Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Waqar and Hashemi

**S1400GEN**, "Ancillary Study to Evaluate Patient and Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in S1400." Drs. Ramsey and Roth.

**S1800**, "A Master Protocol to Evaluate Biomarker-Driven and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Papadimitrakopoulou, Herbst, and Gandara

**EA5163/S1709**, "A Randomized Phase III Study for PD-L1 Positive Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Pembrolizumab in Induction or Maintenance Therapy with Immunosignature-Driven Analysis." Drs. Chiang and Borghaei.

## Concepts in Development

**ALLIANCE/SWOG**, "Phase III Study of Pembrolizumab (MK-3475) vs. Gemcitabine for Second Line Treatment of Malignant Pleural Mesothelioma." Drs. Garland and Verschraegen.

# Lung Committee

"Randomized Phase II Trial to Test the Efficacy of Nintedanib in Combination with Cisplatin and Etoposide for Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer." Dr. Heymach and Dr. Chae.

"A Randomized Phase II Study of Irinotecan versus Irinotecan plus Atezolizumab in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC)." Drs. Karim and Reckamp.

"A Phase II Study of Pembrolizumab Concurrent with Radiotherapy Followed by Pembrolizumab Maintenance in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC) With Borderline Performance Status." Drs. Aljumaily and Mitin. Mentors: Drs. Decker and Wozniack.

PCI vs Active MRI Surveillance in Small-Cell Lung Cancer. Dr. Chad Rusthoven.


## Lung Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S0905	S1206	S1300	S1400	S1400B	S1400C	S1400D	S1400G	S1400I	S1403	S1507	A081105	A151216	C140503	C30607	C30610	C30901	E4512	EA5142	NRGCC003	R1306
Arizona MC, U of	—	3	—	1	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—
Arkansas, U of	2	—	—	3	—	—	1	—	—	—	—	—	—	1	—	2	—	—	—	—	—
Baptist MU-NCORP	—	—	—	10	—	1	—	—	5	1	1	—	15	—	—	1	—	—	—	—	—
Beaumont NCORP	—	—	—	2	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Boston Medical Ctr	—	—	—	4	—	—	—	—	2	—	—	—	2	—	—	—	—	—	—	—	—
Brooke Army Med Ctr	—	—	—	6	—	—	—	—	2	—	—	—	6	—	—	—	—	—	—	—	—
CORA NCORP	—	—	—	7	1	1	—	—	2	—	—	—	2	—	—	—	—	—	—	—	—
CRC West MI NCORP	—	—	—	9	—	—	—	—	1	2	—	—	—	—	—	—	—	—	—	—	—
Carle CC NCORP	—	—	—	3	—	—	1	—	2	—	—	—	—	—	—	—	—	—	—	—	—
Cincinnati MC, U of	—	—	—	4	—	—	—	—	1	—	—	—	7	—	—	3	—	1	—	—	—
City of Hope Med Ctr	—	2	—	12	—	1	—	—	2	—	—	1	4	—	—	—	—	—	—	—	—
Cleveland Clinic OH	—	—	—	9	—	—	—	—	—	—	1	2	11	—	—	—	1	—	—	—	—
Colorado, U of	—	—	1	2	—	1	—	—	1	—	—	2	10	12	—	—	—	—	—	1	1
Columbia MU-NCORP	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Columbus NCORP	—	—	—	11	2	1	—	—	1	3	—	—	—	—	—	1	—	—	—	—	—
Cookeville Reg MC	—	—	—	10	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Davis, U of CA	1	9	—	17	—	2	—	2	3	4	2	1	21	6	—	11	1	1	—	—	—
Dayton NCORP	—	1	—	4	—	—	—	—	1	1	—	—	1	—	—	—	—	—	1	—	—
Essentia Hlth NCORP	—	—	—	7	—	2	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—
Franciscan Res Ctr	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fred Hutchinson CRC	—	—	—	17	1	1	—	1	3	—	—	1	5	—	—	—	—	—	—	—	—
Georgia NCORP	2	—	—	6	—	—	—	—	4	—	1	—	—	—	—	1	—	—	—	—	—
Greenville NCOR	2	—	—	12	1	—	1	1	4	2	—	—	—	—	—	—	—	—	—	—	—
Gulf South MU-NCORP	—	—	—	6	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—
H Lee Moffitt CC	—	—	—	9	—	—	—	—	—	—	—	1	23	—	—	—	—	—	—	—	—
Harrington CC	—	—	—	6	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Harrison Medical Ctr	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hawaii MU-NCORP	—	3	—	6	—	—	—	—	1	4	—	—	—	—	—	—	—	—	—	—	—
Heartland NCORP	8	7	—	39	—	2	1	—	6	1	4	—	—	—	2	7	—	—	—	—	—
Henry Ford Hosp	3	2	—	7	1	—	—	—	—	—	—	1	13	—	—	—	—	—	2	—	—
Irvine, U of CA	—	—	—	8	—	—	—	—	2	—	1	2	4	—	—	—	—	—	—	—	—
Kaiser Perm NCORP	8	—	—	37	—	4	1	—	4	21	—	9	89	—	—	2	—	1	—	—	—
Kansas City NCORP	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kansas, U of	1	—	—	32	—	—	—	—	10	1	—	—	17	—	—	1	—	—	2	—	—
Kentucky, U of	—	—	—	8	—	—	1	—	3	—	—	—	—	—	—	—	—	—	—	—	—
Lahey Hosp & Med Ctr	—	1	—	8	—	1	—	—	1	3	1	—	10	—	—	—	—	—	2	—	2
Loma Linda Univ	—	—	—	4	—	—	—	1	1	—	1	—	1	—	—	—	—	—	—	—	—
Loyola University	—	4	—	9	—	1	—	—	3	—	—	—	4	—	—	—	—	—	2	—	—
MAVERIC	—	—	—	13	1	2	—	—	7	—	—	—	—	—	—	—	—	—	—	—	—

# More than 3 million years of human life saved. Let's Make More Time



## Lung Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S0905	S1206	S1300	S1400	S1400B	S1400C	S1400D	S1400G	S1400I	S1403	S1507	A081105	A151216	C140503	C30607	C30610	C30901	E4512	EA5142	NRGCC003	R1306
MD Anderson CC	55	3	—	16	—	—	1	—	1	—	—	—	—	—	—	—	—	—	—	—	5
MUSC MU-NCORP	—	—	—	1	—	—	—	—	—	—	2	—	—	—	—	1	—	—	—	—	—
Methodist Hospital	—	—	—	5	—	—	—	—	—	—	—	1	4	—	—	—	—	—	—	—	—
Michigan CRC NCORP	4	—	—	26	2	—	1	2	2	6	1	—	—	—	—	—	—	—	—	—	—
Michigan, U of	7	—	—	12	1	2	—	—	3	3	—	—	34	—	—	1	—	—	—	—	—
Mississippi, Univ of	4	—	—	6	1	—	—	—	3	—	—	—	4	—	—	1	—	—	—	—	—
Montana NCORP	5	—	—	13	1	2	—	—	2	2	—	—	—	—	—	—	—	—	—	—	—
Nevada CRF NCORP	—	—	—	4	—	—	—	—	3	—	—	—	—	—	—	—	—	—	—	—	—
New Mexico MU-NCORP	—	—	—	5	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—
Northwest NCORP	—	—	—	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Northwestern Univ	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oklahoma, Univ of	—	—	—	8	—	—	1	1	2	4	—	—	—	—	—	—	—	—	—	—	—
Orange Reg Med Ctr	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—
Oregon Hlth Sci Univ	—	—	—	6	—	—	—	—	4	—	—	—	—	—	—	—	—	—	—	—	—
Ozarks NCORP	—	—	—	16	—	1	1	—	2	1	1	1	1	—	—	—	—	—	—	—	—
PCRC NCORP	2	—	—	13	1	—	—	—	—	—	—	—	4	6	—	—	—	—	—	—	—
Providence Hosp	—	—	—	9	—	—	—	—	—	—	—	—	9	—	—	2	—	1	1	—	—
Rochester, Univ of	—	—	—	15	—	1	—	1	1	1	1	—	—	—	—	—	—	—	—	3	—
San Antonio, U of TX	—	—	—	11	1	1	3	—	2	4	—	—	—	—	—	3	—	—	—	—	—
San Diego, U of CA	—	—	—	9	—	—	—	—	1	6	—	—	3	—	—	—	—	—	—	—	—
So Calif, U of	3	—	—	—	—	—	—	—	—	—	—	—	5	—	—	—	—	—	—	—	—
Southeast COR NCORP	3	1	—	34	1	—	1	—	9	1	—	—	—	—	—	—	—	—	—	—	—
Sutter Cancer RC	—	—	—	3	—	—	—	—	—	—	—	1	4	—	—	—	—	—	2	—	—
Tennessee, U of	—	—	—	—	—	—	—	—	—	—	—	—	—	2	—	—	—	—	—	—	—
Tulane Univ MBCCOP	—	—	—	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Univ of Louisville	—	—	—	—	—	—	—	—	—	—	—	—	5	—	—	—	—	—	—	—	—
Upstate Carolina	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Utah, U of	—	—	—	1	—	1	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—
VAMC Kansas City	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Wayne State Univ	5	—	—	7	—	—	—	1	—	1	1	—	1	—	—	1	—	—	—	—	—
Wichita NCORP	—	—	—	19	—	—	—	1	3	7	—	—	—	—	—	13	—	—	—	—	—
Wisconsin NCORP	—	—	—	4	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—
Yale University	—	11	—	20	—	1	1	—	1	18	—	—	1	13	—	—	—	—	—	3	—
Alliance	—	—	—	290	12	12	10	8	35	17	8	—	—	—	—	—	—	—	—	—	—
CCTG	—	—	—	8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
ECOG-ACRIN	—	—	—	264	6	5	10	3	48	8	8	—	—	—	—	—	—	—	—	—	—
NRG	—	—	—	144	6	5	6	2	16	7	2	—	—	—	—	—	—	—	—	—	—
<b>Total</b>	<b>117</b>	<b>47</b>	<b>1</b>	<b>1,332</b>	<b>39</b>	<b>53</b>	<b>43</b>	<b>25</b>	<b>212</b>	<b>131</b>	<b>37</b>	<b>24</b>	<b>333</b>	<b>27</b>	<b>2</b>	<b>51</b>	<b>2</b>	<b>4</b>	<b>15</b>	<b>3</b>	<b>8</b>



# Lymphoma Committee

## Leadership

Chair: ..... Jonathan W. Friedberg, M.D.  
 Vice-Chair: ..... Sonali M. Smith, M.D.  
 Executive Officer: ..... Susan M. O'Brien, M.D.  
 Statisticians: ..... Michael LeBlanc, Ph.D.  
 ..... Hongli Li, M.S.

## Scientific Leadership

Translational Medicine: ..... Lisa M. Rimsza, M.D.  
 Radiation Oncology: ..... Louis S. Constine, M.D.  
 Imaging: ..... Oliver W. Press, M.D., Ph.D.  
 ..... Lawrence H. Schwartz, M.D.  
 Pathology: ..... Lisa M. Rimsza, M.D.  
 Early Therapeutics: ..... Daruka Mahadevan, M.D., Ph.D.

## Designates

Cancer Control: ..... TBD  
 Data Coordinators: ..... Jeri Jardine  
 ..... Iris Syquia  
 Oncology Research Professionals:  
 CRA: ..... Erin M. Cebula, M.P.H.  
 Nurse: ..... TBD  
 Patient Advocate: ..... Hildy Dillon, M.P.H.  
 Pharmaceutical Science: ..... Lara M. Au, Pharm.D.  
 ..... Craig Elg, Pharm.D.  
 Protocol Coordinator: ..... Veronica Garcia

## Time/Location

Friday, October 13, 2017 4:00 p.m. - 7:00 p.m.  
 Regency B, Ballroom Level, West Tower

### 1. Open Studies:

- a. S1301: Dr. Stiff
- b. S1608: Dr. Barr
- c. EA4151: Dr. Till

### 2. Studies in Development

- a. T-cell lymphoma: Dr. Amengual
- b. DLBCL: Dr. S. Smith

### 3. ASH presentations

- a. S1001 PET Data: Dr. Persky
- b. S1001 Pathology Data: Dr. Stephens

### 4. Monitoring Patients After Lymphoma Treatment: Dr. Phillips and Dr. S. Smith.

### 5. Elderly DLBCL

Geriatric lymphoma: Dr. Supriya Mohile

## Active Studies

**S1608**, "Randomized Phase II Trial in High-Risk Relapsed Refractory Follicular Lymphoma." Dr. Barr. Activated: 8/10/17

**CTSU/A051301**, "A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype." Dr. Stiff. Activated: 7/6/16.

**CTSU/CALGB 501101**, "A Randomized Phase II Trial of Myeloablative versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma." Dr. Mohile. Activated: 6/15/12.

**CTSU/EA4151**, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission. Drs. Fenske, Till, Blum, Crump, Scott, and Kostakoglu. Activated: 8/29/17

**CTSU/EAY131**, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/15.

## Closed Studies

**S0801**, "A Phase II Study of Iodine-131 Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma". Drs. Paul M. Barr, J.W. Friedberg, O.W. Press, and L.M. Rimsza. Activated: 04/01/09. Closed 12/15/2010.

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13. Closed 02/15/2017.

**CTSU/E1411**, "Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB -->R); Arm B = Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation (RBV--> R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB --> LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV --> LR)." Dr. Smith. Activated: 5/22/12. Closed: 9/09/16

**CTSU/E1412**, "Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma." Activated: 8/27/13. Closed: **1/17/17**.

# Lymphoma Committee

## Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1001	A051301	C51101	E1411	E1412	9177
Arizona MC, U of	7	—	—	1	1	—
Arkansas, U of	—	—	—	1	—	—
Brooke Army Med Ctr	—	—	—	—	2	—
CRC West MI NCORP	—	—	—	3	—	—
Cincinnati MC, U of	—	—	—	—	3	—
City of Hope Med Ctr	4	1	—	—	—	—
Cleveland Clinic OH	—	—	—	9	—	4
Colorado, U of	—	—	—	4	—	—
Columbia MU-NCORP	—	—	—	1	3	—
Davis, U of CA	—	—	1	—	—	—
Dayton NCORP	—	—	—	2	—	—
Essentia Hlth NCORP	1	—	—	—	—	—
Fred Hutchinson CRC	2	—	2	4	—	—
Greenville NCORP	2	—	—	—	—	—
Hawaii MU-NCORP	4	—	—	4	1	—
Kaiser Perm NCORP	—	—	—	14	7	—
Kansas City NCORP	6	—	—	3	1	1
Kansas, U of	—	—	2	—	—	—
Kentucky, U of	3	—	—	—	—	4
Loyola University	5	—	—	—	—	—
Michigan CRC NCORP	8	—	—	—	—	—
Montana NCORP	1	—	—	3	4	—
Northwest NCORP	4	—	—	—	—	—
Oregon Hlth Sci Univ	—	—	—	6	—	—
PCRC NCORP	2	—	—	3	—	—
Rochester, Univ of	28	—	3	25	16	9
Southeast COR NCORP	1	—	—	1	—	—
Tennessee, U of	—	—	—	—	—	1
Tulane University	—	—	1	—	—	—
Upstate Carolina	7	—	—	1	—	—
Wayne State Univ	—	—	—	1	1	—
Wichita NCORP	6	—	—	—	1	—
Yale University	6	—	—	—	—	—
Alliance	40	—	—	—	—	—
ECOG-ACRIN	20	—	—	—	—	—
NRG	2	—	—	—	—	—
<b>Total</b>	<b>159</b>	<b>1</b>	<b>9</b>	<b>86</b>	<b>39</b>	<b>19</b>

# Melanoma Committee

## Leadership

Chair: ..... Antoni Ribas, M.D., Ph.D.  
 Vice-Chair: ..... Kenneth F. Grossman, M.D., Ph.D.  
 Executive Officer: ..... Christopher W. Ryan, M.D.  
 Statisticians: ..... Michael Wu, Ph.D.  
 ..... Megan Othus, Ph.D.  
 ..... James Moon, M.S.  
 ..... Hongli Li, M.S.  
 ..... Michaela Latkovic-Taber, M.P.H.

## Scientific Leadership

Translational Medicine: ..... William E. Carson, III, M.D.  
 Radiation Oncology: ..... Evan J. Wuthrick, M.D.  
 Surgery: ..... Robert H.I. Andtbacka, M.D.  
 Imaging: ..... Kenneth F. Grossman, M.D., Ph.D.  
 ..... Martin Allen-Auerbach, M.D.  
 Medical Oncology: ..... Lawrence E. Flaherty, M.D.  
 Pathology: ..... TBD  
 Non-Melanoma Skin Cancer: ..... Sancy A. Leachman, M.D., Ph.D.  
 Early Therapeutics: ..... Jeffrey A. Sosman, M.D.  
 SWOG's ECOG Liaison: ..... Kenneth F. Grossmann, M.D., Ph.D.  
 ECOG's SWOG Liaison: ..... David Lawson, M.D.  
 ..... Andrew Poklepovich, M.D.

## Designates

Cancer Control Liaison: ..... Sancy Leachman, M.D., Ph.D.  
 Data Coordinator: ..... Diana Heaney  
 ..... Joanna Dur  
 ..... Krystle Pagarigan  
 Oncology Research Professionals:  
 CRA: ..... Kacie L. Simpson, B.S., C.C.R.P.  
 Nurse: ..... Lisa S. Morgan, R.N., O.C.N.  
 Patient Advocate: ..... Valerie Guild, M.B.A.  
 Pharmaceutical Science: ..... Sun "Coco" Yang, Pharm.D., Ph.D.  
 Protocol Coordinator: ..... Danae Campos

## Time/Location

Friday, October 13, 2017 9:30 a.m. - 11:30 a.m.  
 Crystal B, Lobby Level, West Tower

**9:30-11:30 a.m.:** Presentation of ongoing SWOG melanoma committee clinical trials

## Active Studies

**S1320**, "A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma." Dr. Algazi. Activated: 7/22/14.

**S1512**, "A Phase II Study of PD-1 Blockade with Pembrolizumab in Patients with Locally Advanced and Metastatic Desmoplastic Melanoma (DM)." Drs. K. Kendra and S. Hu-Lieskovan. Activated: 10/20/16.

**S1616**, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent." Drs. A. VanderWalde and T. Ribas. Activated 7/17/17.

**S1221**, "Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer." Drs. A. Algazi and T. Ribas. Activated: 7/1/13. Temporarily closed: 10/31/16.

**CTSU/EA6134**, "A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma". Dr. Chmielowski. Activated: 7/13/15.

**CTSU/EA6141**, "Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." Dr. Kim. Activated: 9/10/15. Temporarily closed: 6/23/17.

## Upcoming Studies

**S1607**, "A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan.

## Follow Up on Recently Closed Studies

**S1404**, "A Phase III Randomized Trial Comparing Physician/Patient Choice of either High-Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High-Risk Resected Melanoma." Drs. Grossmann and Patel. Activated 10/15/15. Closed: 8/15/17.

*“With support from Hope, advocates are working with SWOG to improve the quality of life for patients, both during and after treatment.”*


# Helping Advocates Do More

*SWOG advocates serve as the voice of the patient in clinical trials – from the original concept to final publication.*

*Help The Hope Foundation continue its support of their invaluable efforts.*

*Text “SWOG” to 41444 to give today.*

**25 Years of Supporting SWOG**



*Amy Geschwender, PhD  
SWOG Patient Advocate,  
Symptom Control & Quality  
of Life Committee*

## THE HOPE FOUNDATION

*Because answers to cancers come from clinical trials*



## Melanoma Committee

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1221	S1320	S1404	S1512	E3612	EA6134	EA6141
Arizona MC, U of	—	2	10	—	—	—	—
Arkansas, U of	—	5	11	—	—	1	—
Baylor Univ Med Ctr	—	—	12	—	—	—	—
Boston Medical Ctr	—	1	—	—	—	—	—
CORA NCORP	—	1	8	—	—	—	—
CRC West MI NCORP	—	2	13	—	—	—	—
Cedars-Sinai Med Ctr	—	—	7	—	—	—	—
Cincinnati MC, U of	—	—	3	—	—	—	—
City of Hope Med Ctr	—	—	8	—	—	1	3
Cleveland Clinic OH	—	—	23	—	—	—	—
Colorado, U of	5	2	29	—	—	1	—
Columbia MU-NCORP	—	—	3	—	—	—	—
Columbus NCORP	—	—	4	—	—	—	—
Davis, U of CA	—	—	2	—	—	—	—
Dayton NCORP	—	1	7	—	—	—	—
Essentia Hlth NCORP	—	—	1	—	—	—	—
Georgia NCORP	—	—	17	—	—	—	—
Greenville NCORP	—	—	—	—	1	—	—
Gulf South MU-NCORP	—	—	3	—	—	—	—
H Lee Moffitt CC	—	—	48	—	—	—	—
Hawaii MU-NCORP	—	1	3	—	—	—	—
Heartland NCORP	—	5	24	—	—	—	—
Irvine, U of CA	—	—	1	—	—	—	—
Kaiser Perm NCORP	—	24	68	—	3	2	20
Kansas City NCORP	—	—	1	—	—	—	1
Kansas, U of	—	12	24	—	—	2	—
Lahey Hosp & Med Ctr	—	1	4	—	—	—	—
Los Angeles, U of CA	6	2	22	—	—	3	—
Loyola University	—	4	1	—	—	—	—
MD Anderson CC	—	—	40	—	—	—	—
Michigan CRC NCORP	—	—	8	—	—	—	—



## Melanoma Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending July 30, 2017 | Includes studies that are currently open, or that closed since Jan. 1, 2016.

	S1221	S1320	S1404	S1512	E3612	EA6134	EA6141
Michigan, U of	5	3	12	—	—	—	—
Mississippi, Univ of	—	—	1	—	—	—	—
Montana NCORP	—	—	4	—	—	—	—
Mt Sinai Med Ctr	—	—	10	—	—	—	—
Nevada CRF NCORP	—	2	—	—	—	—	—
New Mexico MU-NCORP	—	—	8	—	—	—	—
Northwest NCORP	—	—	9	—	—	—	—
Northwestern Univ	—	—	13	—	1	—	—
Ohio State Univ	6	9	31	1	—	2	—
Oregon Hlth Sci Univ	—	—	10	—	—	—	—
Ozarks NCORP	—	2	4	—	—	—	—
PCRC NCORP	2	2	16	—	—	—	—
Rochester, Univ of	—	3	6	—	—	—	—
San Antonio, U of TX	—	—	7	—	—	—	1
San Diego, U of CA	—	—	6	—	—	—	—
San Francisco, U-CA	1	8	—	—	—	—	—
So Calif, U of	—	—	—	1	—	—	—
Southeast COR NCORP	—	5	9	—	—	—	—
Sutter Cancer RC	2	—	5	—	—	2	5
Tennessee, U of	—	—	4	—	—	—	—
Utah, U of	—	6	30	—	—	—	—
VAMC Kansas City	—	—	1	—	—	—	—
Wayne State Univ	—	—	9	—	—	2	—
Wichita NCORP	—	4	11	—	—	—	—
Wisconsin NCORP	—	—	6	—	—	—	—
Yale University	—	—	5	—	—	—	6
Alliance	—	12	136	—	—	—	—
CCTG	—	—	107	—	—	—	—
ECOG-ACRIN	—	38	260	—	—	—	—
NRG	—	7	86	—	—	—	—
<b>Total</b>	<b>27</b>	<b>164</b>	<b>1,211</b>	<b>2</b>	<b>5</b>	<b>16</b>	<b>36</b>



# Publication List by Committee

The publications listed below were received by the group chair's office as published, accepted, and submitted or reflect change in publication status since the SWOG 2017 Spring Group Meeting. Not included are submitted or accepted publications where posting is not permitted due to journal embargo policy (e.g., NEJM). Conference abstracts are also not included.

## Adolescent and Young Adult (AYA) Committee

### Published/Accepted Manuscripts

Practice makes perfect: The rest of the story in testicular cancer as a model curable neoplasm. T Tandstad, C Kollmannsberger, B Roth, C Jeldres, S Gillissen, K Fizazi, S Daneshmand, W Lowrance, N Hanna, C Albany, R Foster, G Cohn-Cedermark, D Feldman, T Powles, M Lewis, P Grimison, D Bank, C Porter, P Albers, M De Santis, S Srinivas, G Bosl, C Nichols. *Journal of Clinical Oncology*, 2017 Aug 30 [Epub ahead of print]. <https://www.ncbi.nlm.nih.gov/pubmed/28854068>

### Submitted Manuscripts

No publication information for this cycle.

## Barlogie-Salmon Myeloma Committee

### Published/Accepted Manuscripts

S0777/other Proteasome inhibitors in cancer therapy. EE Manasanch, RZ Orlowski. *Nature Reviews Clinical Oncology* Jul;14(7):417-433, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28117417>

### Submitted Manuscripts

No publication information for this cycle.

## Breast Committee

### Published/Accepted Manuscripts

S0221 Supplement use and chemotherapy-induced peripheral neuropathy in patients treated in a SWOG cooperative group trial (S0221): the DELCaP Study. G Zirpoli, S McCann, L Sucheston-Campbell, D Hershman, G Ciupak, W Davis, J Unger, H Moore, JA Stewart, C Isaacs, T Hobday, M Salim, R Livingston, G Hortobagyi, J Gralow, D Hayes, G Budd, K Albain, C Ambrosone. *Journal of the National Cancer Institute*, in press. [see also SCQOLCmte]

S9630 A Phase III randomized comparison of medroxyprogesterone acetate versus observation for the prevention of endometrial pathology in postmenopausal patients with breast cancer treated with adjuvant tamoxifen: SWOG S9630. RK Potkul, JM Unger, RB Livingston, S Wilczynski, C Salomon, B Smith, L Wong, DL Campbell, SJ Vogel, GL

Anderson, GE Goodman, PH Brown, FL Meyskens, KS Albain. *NPJ Breast Cancer*, 2016 Aug 10;2:16024. [see also Prevention & Epidemiology Cmte] <https://www.ncbi.nlm.nih.gov/pubmed/28721383>

S9630/Multiple Studies How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? KD Crew, KS Albain, DL Hershman, JM Unger, SS Lo. *NPJ Breast Cancer*, May 19;3:20, 2017. [commentary] [see also Prevention & Epidemiology Cmte] <https://www.ncbi.nlm.nih.gov/pubmed/28649660>

JMA27 Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard K, Ingle J, Budd G, Ellis M, Sledge G, Rabaglio M, Han L, Elliott C, Shepherd LE, Goss PE, Ali S. Osteoporosis therapy prolongs event-free survival in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. *Cancer* Jul 1;123(13):2444-2451, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28464211>

CCTG MA32 Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel J, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee S, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. *Breast Cancer Research and Treatment* Jul;164(2):371-378, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28447237>

Z1071 Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance). JC Boughey, KV Ballman, LM McCall, EA Mittendorf, WF Symmans, TB Julian, D Byrd, KK Hunt. *Annals of Surgery* Jun 27 [Epub ahead of print], 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28657941>

### Submitted Manuscripts

S0800 Effects of neoadjuvant chemotherapy on tumor infiltrating lymphocytes and PD-L1 expression in the SWOG S0800 clinical trial V Pelekanou, WE Barlow, ZA Nahleh, B Wasserman, Y-C Lo, M-K von Wahlde, D Hayes, GN Hortobagyi, J Gralow, D Tripathy, P Porter, RB Livingston, B Szekely, C Hatzis, DL Rimm, L Pusztai. *JAMA Oncology*, under review.

# Publication List by Committee

**S9313** Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313). P Sharma, WE Barlow, AK Godwin, H Pathak, K Isakova, KM Timms, AR Hartman, RJ Wenstrup, HM Linden, D Tripathy, GN Hortobagyi, DF Hayes. Journal of Clinical Oncology, under review.

## Cancer Control & Prevention

### Cancer Care Delivery Committee

#### Published/Accepted Manuscripts

**S1415CD** A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: The TrACER study. A Bansal, SD Sullivan, DL Hershman, GH Lyman, WE Barlow, JS McCune, SD Ramsey. Journal of Comparative Effectiveness Research, Journal of Comparative Effectiveness Research, 2017 Jul;6(5):461-470. <https://www.ncbi.nlm.nih.gov/pubmed/28686055>

**Multiple Studies\*** The effect of positive SWOG treatment trials on survival of patients with cancer in the US population. JM Unger, M LeBlanc, CD Blanke. JAMA Oncology, 2017 Jun 5. doi: 10.1001/jamaoncol.2017.0762. [\*studies: SWG01, SWG02, S7436, S7704, S7817, S8494, S8501, S8591, S8624, S8710, S8736, S8797, S8814, S8892, S8897, S8949, S9008, S9126, S9210, S9308, S9916, S0226, S0777]. <https://www.ncbi.nlm.nih.gov/pubmed/28586789>

Characterizing 18 years of death with dignity in Oregon. C Blanke, M LeBlanc, D Hershman, L Ellis, F Meyskens. JAMA Oncology, 2017 Apr 6 [Epub ahead of print]. <https://www.ncbi.nlm.nih.gov/pubmed/28384683>

Feasibility of a centralized clinical trials coverage analysis: a joint initiative of the American Society for Clinical Oncology (ASCO) and the National Cancer Institute (NCI). CM Szczepanek, P Hurley, MJ Good, A Denicoff, K Willenberg, C Dawson, D Kurbegov. Journal of Oncology Practice, Jun;13(6):395-400, 201. <https://www.ncbi.nlm.nih.gov/pubmed/28481681>

Responding to patient requests for hastened death: physician aid in dying and the clinical oncologist. RA Spence, CD Blanke, TJ Keating, et al. Journal of Oncology Practice, in press.

#### Submitted Manuscripts

**S0000/S9217** The scientific impact and value of large, NCI-sponsored randomized Phase III cancer prevention trials. JM Unger, WE Barlow, CM Tangen, SD Ramsey, IM Thompson, Jr., EA Klein, M LeBlanc, CD Blanke, PJ

Goodman, LM Minasian, DL Hershman. JCO Clinical Cancer Informatics, under review.

**S9217** Long term risk of prostate cancer on the Prostate Cancer Prevention Trial (SWOG S9217). JM Unger, DL Hershman, C Till, CM Tangen, WE Barlow, SD Ramsey, PJ Goodman, IM Thompson, Jr. JAMA Oncology, under review.

**Multiple Studies\*** Survival by Hispanic ethnicity among SWOG cancer clinical trials patients. M Chavez-MacGregor, JM Unger, A Moseley, S Ramsey, DL Hershman. Cancer Epidemiology Biomarkers and Prevention, under review. [\*studies: S8516, S8600, S8809, S8814, S8894, S8897, S8905, S9008, S9031, S9125, S9210, S9240, S9304, S9308, S9313, S9321, S9333, S9346, S9349, S9415, S9420, S9509, S9623, S9704, S9800, S9911, S9916, S0003, S0012, S0016, S0033, S0106, S0221, S0226, S0232, S0307, S0421, S0500].

**Multiple Studies\*** History of diabetes and outcome among participants 65 or older in SWOG clinical trials. DL Hershman, C Till, JD Wright, S Ramsey, W Barlow, J Unger. JCO Clinical Cancer Informatics, revised/resubmitted. [\*studies: S0003, S0023, S0033, S0124, S0205, S0221, S0226, S0232, S0307, S0421, S0500, S0777, S9321, S9346, S9916].

### Cancer Survivorship Committee

#### Published/Accepted Manuscripts

**C89803** Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). MA Fuchs, C. Yuan, K Sato, D Niedzwiecki, X Ye, LB Saltz, RJ Mayer, RB Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, F Innocenti, RS Warren, MM Bertagnolli, S Ogino, EL Giovannucci, E Horvath, JA Meyerhardt, K Ng. Annals of Oncology Jun 1;28(6):1359-1367, 2017. [see also GI Cmte] <https://www.ncbi.nlm.nih.gov/pubmed/?term=hantel+a+vitamin+d>

#### Submitted Manuscripts

**S0424** Smoking, sex and non-small cell lung cancer: examination of steroid hormone receptors in lung tumor tissue in SWOG S0424. T-Y D Cheng, AK Darke, MW Redman, GR Zirpoli, W Davis, R Payne Ondracek, W Bshara, A Omilian, R Kratzke, ME Reid, JR Molina, JM Kolesar, Y Chen, RM MacRae, J Moon, P Mack, DR Gandara, K Kelly, RM Santella, KS Albain, CB Ambrosone. Journal of the National Cancer Institute, pending revision/resubmission. [see also Lung Cmte]

**A011401** Randomized Phase iii trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (A011401): study design and rationale. JA Ligibel, WT Barry, C Alfano, DL Hershman, M Irwin, ML Neuhaus, CA Thomson,



# Publication List by Committee

LM Delahanty, E Frank, P Spears, ED Paskett, JO Hopkins, V Bernstein, V Stearns, J White, C Hudis, EP Winer, TA Wadden, PJ Goodwin. NPJ Breast Cancer, under review .

**C89803** Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis in relation to cancer recurrence and survival. E Van Blarigan, C Fuchs, D Niedzwiecki, X Ye, S Zhang, M Song, L Saltz, R Mayer, R Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, S Ogino, E Giovannucci, J Meyerhardt. Cancer Epidemiology, Biomarkers & Prevention, submitted. [see also GI Cmte]

**C89803** Artificially sweetened beverage intake and outcome in stage iii colon cancer: results from CALGB 89803 (Alliance). C Fuchs, B Guercio, S Zhang, D Niedzwiecki, Z Yee, Y Li, A Babic, V Morales-Oyarvide, L Saltz, RJ Mayer, R Mowat, R Whittom, A Hantel, A Benson, DM Atienza, M Messino, H Kindler, A Venook, S Ogino, E Zoltick, M Stempfeler, K Ng, K Wu, W Willett, E Giovannucci, J Meyerhardt. Journal of Clinical Oncology, submitted. [see also GI Cmte]

## Prevention & Epidemiology Committee

### Published/Accepted Manuscripts

**S0000A** Association of antioxidant supplement use and dementia in The Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). RJ Kryscio, EL Abner, A Caban-Holt, M Lovell, P Goodman, J Hartline, AK Darke, M Yee, J Crowley, FA Schmitt. JAMA Neurology May 1;74(5):567-573, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28319243>

**S0000 S9217** A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: linked PCPT and SELECT cohorts. E Platz, I Kulac, J Barber, C Drake, C Joshu, W Nelson, MS Lucia, EA Klein, SM Lippman, H Parnes, IM Thompson, P Goodman, C Tangen, AM De Marzo. Cancer Epidemiology, Biomarkers and Prevention, 2017 Jul 28. pii: cebp.0503.2017 [Epub ahead of print]. <https://www.ncbi.nlm.nih.gov/pubmed/28754796>

**S0820** Updates on S0820/PACES: Preventing adenomas of the colon with eflornithine and sulindac. J Zell, R Krouse, N You. Bulletin of the American College of Surgeons, in press.

**S9217** Interactions of the insulin-like growth factor axis and vitamin D in prostate cancer risk in the Prostate Cancer Prevention Trial. FL Miles, PJ Goodman, C Tangen, KC Torkko, JM Schenk, X Song, M Pollak, IM Thompson, ML Neuhaus. Nutrients 2017 Apr 12;9(4). pii: E378. doi: 10.3390/nu9040378. <https://www.ncbi.nlm.nih.gov/pubmed/28417914>

**S9217** Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. D Winchester, C Till, PJ Goodman, CM Tangen, RM Santella, TL Johnson-Pais, RJ Leach, J Xu, SL Zheng, IM Thompson, MS Lucia, SM Lippman, HL Parnes, WB Isaacs, AM De Marzo, CG Drake, EA Platz. Prostate Jun;77(8):908-919, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28317149>

**S9217/Multiple Studies** A pooled analysis of 15 prospective cohort studies on the association between fruit, vegetable, and mature bean consumption and risk of prostate cancer. J Petimar, KM Wilson, K Wu, D Albanes, PA van den Brandt, MB Cook, GG Giles, E Giovannucci, GG Goodman, PJ Goodman, N Håkansson, K Helzlsouer, LN Kolonel, LM Liao, S Männistö, ML McCullough, R Milne, ML Neuhaus, Y Park, EA Platz, N Sawada, JM Schenk, S Tsugane, B Verhage, M Wang, Y Wang, LR Wilkens, A Wolk, RG Ziegler, SA Smith-Warner. Cancer Epidemiology Biomarkers & Prevention Aug;26(8):1276-1287, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28446545>

**S9630** A Phase III randomized comparison of medroxyprogesterone acetate versus observation for the prevention of endometrial pathology in postmenopausal patients with breast cancer treated with adjuvant tamoxifen: SWOG S9630. RK Potkul, JM Unger, RB Livingston, S Wilczynski, C Salomon, B Smith, L Wong, DL Campbell, SJ Vogel, GL Anderson, GE Goodman, PH Brown, FL Meyskens, KS Albain. NPJ Breast Cancer, 2016 Aug 10;2:16024. [see also Breast Cmte] <https://www.ncbi.nlm.nih.gov/pubmed/28721383>

**S9630/Multiple Studies** How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? KD Crew, KS Albain, DL Hershman, JM Unger, SS Lo. NPJ Breast Cancer, May 19;3:20, 2017. [also under Breast Cmte] <https://www.ncbi.nlm.nih.gov/pubmed/28649660>

### Submitted Manuscripts

**S9217** Associations between genetic polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. L Tang, ME Platak, S Yao, C Till, PJ Goodman, CM Tangen, Y Wu, EA Platz, ML Neuhaus, FZ Stanczyk, JKV Reichardt, RM Santella, A Hsing, WD Figg, SM Lippman, IM Thompson, CB Ambrosone. Carcinogenesis, submitted.

# Publication List by Committee

## Symptom Control & Quality of Life Committee

### Published/Accepted Manuscripts

**S0221** Supplement use and chemotherapy-induced peripheral neuropathy in patients treated in a SWOG cooperative group trial (S0221): the DELCaP Study. G Zirpoli, S McCann, L Sucheston-Campbell, D Hershman, G Ciupak, W Davis, J Unger, H Moore, JA Stewart, C Isaacs, T Hobday, M Salim, R Livingston, G Hortobagyi, J Gralow, D Hayes, G Budd, K Albain, C Ambrosone. *Journal of the National Cancer Institute*, in press. [see also Breast Cmte]

**S0702** Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702. CH Van Poznak, A Darke, CM Moinpour, RA Bagramian, MM Schubert, JR Gralow, JL Wade, III, JM Unger. *Supportive Care in Cancer*, Apr;25(4):1191-1199, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/27928641>

### Submitted Manuscripts

**S0715** Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). DL Hershman, JM Unger, KD Crew, C Till, H Greenlee, LM Minasian, CM Moinpour, DL Lew, L Fehrenbacher, JL Wade, S-F Wong, MJ Fisch, NL Henry, KS Albain. *Journal of the National Cancer Institute*, pending revision/resubmission.

**S1202** Randomized multicenter placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early stage breast cancer: SWOG S1202. NL Henry, JM Unger, AF Schott, L Fehrenbacher, PJ Flynn, DM Prow, CW Sharer, G Von Burton, CS Kuzma, A Moseley, DL Lew, M Fisch, C Moinpour, DL Hershman, JL Wade, III. *Journal of Clinical Oncology*, under review.

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). MR Mahoney, JA Sloan, JM Hubbard, AD Tan, H Liu, RM Goldberg, SG Nair, AF Shields, S Gill, B Jahagirdar, AB Benson, DJ Sargent, SR Alberts. *Journal of Patient-Reported Outcomes*, under review. [see also GI Cmte]

## Early Therapeutics & Rare Cancers Committee

No publication information for this cycle.

## Gastrointestinal Committee

### Published/Accepted Manuscripts

**S0518** Phase III prospective randomized comparison trial of depot octreotide plus interferon alpha-2b versus depot octreotide plus

bevacizumab in advanced, poor prognosis carcinoid patients: SWOG S0518. JC Yao, KA Guthrie, C Moran, JR Strosberg, MH Kulke, J Ang Chan, N Loconte, RR McWilliams, EM Wolin, B Mattar, S McDonough, H Chen, CD Blanke, HS Hochster. *Journal of Clinical Oncology* May 20;35(15):1695-1703, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28384065>

**CALGB/SWOG 80405** Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: A randomized trial. AP Venook, D Niedzwiecki, H-J Lenz, F Innocenti, B Fruth, JA Meyerhardt, D Schrag, C Greene, BH O'Neil, JE Shaw, JN Atkins, A El-Khoueiry, S Berry, BN Polite, EM O'Reilly, RM Goldberg, HS Hochster, RL Schilsky, MM Bertagnolli, RJ Mayer, CD Blanke. *Journal of the American Medical Association* Jun 20;317(23):2392-2401, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28632865>

**C89803** Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). MA Fuchs, C. Yuan, K Sato, D Niedzwiecki, X Ye, LB Saltz, RJ Mayer, RB Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, F Innocenti, RS Warren, MM Bertagnolli, S Ogino, EL Giovannucci, E Horvath, JA Meyerhardt, K Ng. *Annals of Oncology* Jun 1;28(6):1359-1367, 2017. [see also Ca Surv Cmte] <https://www.ncbi.nlm.nih.gov/pubmed/?term=hantel+a+vitamin+d>

### Submitted Manuscripts

**C89803** Artificially sweetened beverage intake and outcome in stage iii colon cancer: results from CALGB 89803 (Alliance). C Fuchs, B Guercio, S Zhang, D Niedzwiecki, Z Yee, Y Li, A Babic, V Morales-Oyarvide, L Saltz, RJ Mayer, R Mowat, R Whittom, A Hantel, A Benson, DM Atienza, M Messino, H Kindler, A Venook, S Ogino, E Zoltick, M Stempfer, K Ng, K Wu, W Willett, E Giovannucci, J Meyerhardt. *Journal of Clinical Oncology*, submitted. [see also Ca Surv Cmte]

**C89803** Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis in relation to cancer recurrence and survival. E Van Blarigan, C Fuchs, D Niedzwiecki, X Ye, S Zhang, M Song, L Saltz, R Mayer, R Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, S Ogino, E Giovannucci, J Meyerhardt. *Cancer Epidemiology, Biomarkers & Prevention*, submitted. [see also Ca Surv Cmte]

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). MR Mahoney, JA Sloan, JM Hubbard, AD Tan, H Liu, RM Goldberg, SG Nair, AF Shields, S Gill, B Jahagirdar, AB Benson, DJ Sargent, SR Alberts. *Journal of Patient-Reported Outcomes*, under review. [see also SXCQOL Cmte]

# Publication List by Committee

## Genitourinary Committee

**Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees**

### Published/Accepted Manuscripts

**S0421** Validation of the association of RECIST changes with survival in men with metastatic castration resistant prostate cancer treated on SWOG study S0421. G Sonpavde, GR Pond, M Plets, CM Tangen, MHA Hussain, PN Lara, Jr, A Goldkorn, MG Garzotto, PC Mack, CS Higano, NJ Vogelzang, IM Thompson, Jr, PW Twardowski, PJ Van Veldhuizen, Jr, N Agarwal, MA Carducci, J Monk, DI Quinn. *Clinical Genitourinary Cancer*, 2017 May 10 [Epub ahead of print]. <https://www.ncbi.nlm.nih.gov/pubmed/28579151>

**S1014** Abiraterone acetate for metastatic prostate cancer in patients with suboptimal biochemical response to hormone induction TW Flaig, M Plets, M Hussain, N Agarwal, N Mitsiades, HA Deshpande, U Vaishampayan, IM Thompson. *JAMA Oncology* 2017 Mar 30 [Epub ahead of print]. <https://www.ncbi.nlm.nih.gov/pubmed/28358937>

**E2805** Retroperitoneal lymphadenectomy in high-risk non-metastatic renal cell carcinoma: an analysis of the ASSURE (ECOG 2805) Adjuvant Trial. BT Ristau, J Manola, NB Haas, DY Heng, EM Messing, CG Wood, CJ Kane, RS DiPaola, RG Uzzo. *Journal of Urology* 2017 Jul 17 [Epub ahead of print]. <https://www.ncbi.nlm.nih.gov/pubmed/28728992>

### Submitted Manuscripts

**S0337** Immediate post TURBT instillation of gemcitabine vs saline for suspected low grade bladder cancer: SWOG S0337. EM Messing, CM Tangen, SP Lerner, DM Sahasrabudhe, TM Koppie, DP Wood, Jr, PC Mack, RS Svatek, CP Evans, KS Hafez, DJ Culkin, TC Brand, LI Karsh, JM Holzbeierlein, SS Wilson, G Wu, M Plets, NJ Vogelzang, IM Thompson, Jr. *JAMA*, submitted.

**S0421** Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: results from SWOG S0421. PN Lara, Jr, M Plets, C Tangen, E Gertz, NJ Vogelzang, M Hussain, PW Twardowski, MG Garzotto, JP Monk, M Carducci, A Goldkorn, PC Mack, DI Quinn, IM Thompson, M Van Loan. *Clinical Cancer Research*, submitted.

**S0925** Circulating microRNAs and treatment response in SWOG S0925, a randomized Phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. HH Cheng, M Plets, H Li, CS Higano, CM Tangen, N Agarwal, NJ Vogelzang, M Hussain, IM Thompson, Jr, M Tewari, EY Yu. *Prostate*, revised/resubmitted.

**S1107** Parallel (randomized) Phase ii evaluation of tivantinib (arq197) and tivantinib in combination with erlotinib in papillary renal cell carcinoma: SWOG S1107. PW Twardowski, CM Tangen, X Wu, MR Plets, ER Plimack, N Agarwal, NJ Vogelzang, J Wang, S Tao, IM Thompson, Jr, P Lara Jr. *Clinical Cancer Research*, under review.

**E3805** Quality of life (QOL) during treatment with chemohormonal therapy: analysis of ECOG 3805 chemohormonal androgen ablation randomized trial in prostate cancer (CHAARTED). A Morgans, Y Chen, C Sweeney, D Jarrard, E Plimack, B Gartrell, M Carducci, M Hussain J. Garcia, D Cella, R DiPaola, L Patrick-Miller. *Journal of Clinical Oncology*, submitted. [see also SXCQOL Cmtc]

**E3805** Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized Phase III E3805 Trial. CE Kyriakopoulos, Y-H Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, Y Wong, N Hahn, M Kohli, MM Cooney, R Dreicer, NJ Vogelzang, J Picus, D Shevrin, M Hussain, JA Garcia, RS DiPaola, CJ Sweeney. *Journal of Clinical Oncology*, submitted.

## Leukemia Committee

### Published/Accepted Manuscripts

**S1117** A randomized Phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia CMML): North American Intergroup Study SWOG S1117. MA Sekeres, M Othus, A List, O Odenike, R Stone, SD Gore, M Litzow, R Buckstein, M Fang, D Roulston, C Bloomfield, A Moseley, Y Zhang, M. Velasco, R Gaur, E Atallah, EC Attar, F Appelbaum, H Erba. *Journal of Clinical Oncology* Aug 20;35(24): 2745-2753, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28486043>

**C10603** Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, CD Bloomfield, C Thiede, TW Prior, K Döhner, G Marcucci, F Lo-Coco, RB Klisovic, A Wei, J Sierra, MA Sanz, JM Brandwein, T de Witte, D Niederwieser, FR Appelbaum, BC Medeiros, MS Tallman, J Krauter, RF Schlenk, A Ganser, H Serve, G Ehninger, S Amadori, RA Larson, H Döhner. *New England Journal of Medicine* Aug 3;377(5):454-464, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28644114>

### Submitted Manuscripts

**S0106 E1900** Higher clinical trial accrual volume improves outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN Study. BC Medeiros, M Othus, MS Tallman, Z Sun, HF Fernandez, JM Rowe, HM Lazarus, FR Appelbaum, SM Luger, MR Litzow, HP Erba. *Haematologica*, submitted

# Publication List by Committee

**S0919** Report of the relapsed/ refractory cohort of SWOG S0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia. AS Advani, Hongli Li, LC Michaelis, BC Medeiros, M Liedtke, AF List, K O'Dwyer, M Othus, HP Erba, FR Appelbaum. Blood Advances, submitted.

**S1612** Intergroup LEAP trial (S1612): a randomized rolling-arms platform to test therapeutics in less-fit older adults with AML. RB Walter, LC Michaelis, M Othus, GL Uy, JP Radich, RF Little, S Hita, L Saini, JM Foran, AT Gerds, HD Klepin, AE Hay, JE Lancet, S Couban, MR Litzow, RM Stone, HP Erba. Blood, under review.

**Multiple Studies\*** Impact of specimen heterogeneity on biomarkers in repository samples from patients with AML: a SWOG report. E Pogossova-Agadjanyan, A Moseley, M Othus, FR Appelbaum, T Chauncey, I-M L Chen, HP Erba, JE Godwin, M Fang, K Kopecky, AF List, GL Pogosso, JP Radich, CL Willman, BL Wood, S Meshinchi, DL Stirewalt. Biopreservation and Biobanking, submitted. [\*studies:S9031, S9333, S0106, S0112]

## Lung Committee

### Published/Accepted Manuscripts

**S0635 S0636** Paired Phase II studies of erlotinib/bevacizumab in advanced bronchioloalveolar carcinoma or in never-smokers with advanced non-small-cell lung cancer (NSCLC): SWOG S0635 and S0636 Trials. HL West, J Moon, AJ Wozniak, P Mack, FR Hirsch, MJ Bury, M Kwong, DD Nguyen, DF Moore, J Miao, M Redman, K Kelly, DR Gandara. Clinical Lung Cancer, Jul 6 [Epub ahead of print], 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28801183>

**S0819** A randomized, Phase iii study of carboplatin/paclitaxel or carboplatin/paclitaxel/ bevacizumab with or without concurrent cetuximab investigating EGFR FISH in patients with advanced non-small cell lung cancer: SWOG S0819. R Herbst, M Redman, E Kim, T Semrad, L Bazhenova, G Masters, K Oettel, P Guaglianone, C Reynolds, A Karnad, S Arnold, M Varella-Garcia, J Moon, P Mack, C Blanke, F Hirsch, K Kelly, DR Gandara. Lancet Oncology, in press.

**S0905** Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905). AS Tsao, MD, J Moon, II Wistuba, MD, NJ Vogelzang, GP Kalemkerian, MW Redman, DR Gandara, K Kelly. Journal of Thoracic Oncology Aug;12(8):1299-1308, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28599887>

**Multiple Studies\*/Other** A pooled analysis of individual patient data of concurrent chemoradiotherapy for stage 3 non-small-cell lung cancer in elderly patients compared to younger patients who participated in United States National Cancer Institute Cooperative Group studies. TE Stinchcombe, Y Zhang, EE Vokes, J Schiller, JD Bradley, Karen Kelly, W Curran, SE Schild, B Movsas, G Clamon, R Govindan, GR Blumenschein, MA Socinski, NE Ready, WL Akerley, HJ Cohen, H Pang, X Wang. Journal of Clinical Oncology, Sep 1;35(25):2885-2892, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28493811>

### Submitted Manuscripts

**S0424** Smoking, sex and non-small cell lung cancer: examination of steroid hormone receptors in lung tumor tissue in SWOG S0424. T-Y D Cheng, AK Darke, MW Redman, GR Zirpoli, W Davis, R Payne Ondracek, W Bshara, A Omilian, R Kratzke, ME Reid, JR Molina, JM Kolesar, Y Chen, RM MacRae, J Moon, P Mack, DR Gandara, K Kelly, RM Santella, KS Albain, CB Ambrosone. Journal of the National Cancer Institute, pending revision/resubmission. [see also Ca Surv Cmte]

**E1505** Randomized Phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505. H Wakelee, S Dahlberg, S Keller, W Tester, D Gandara, S Graziano, A Adjei, N Leighl, S Aisner, J Rothman, J Patel, MD Sborov, S McDermott, R Perez-Soler, A Traynor, C Butts, T Evans, L Horn, SS Ramalingam, J Schiller on behalf of ECOG-ACRIN. Lancet Oncology, pending revision/submission.

## Lymphoma Committee

### Published/Accepted Manuscripts

**E2496/COG\*** Outcomes in adolescents and young adults (AYA) with hodgkin lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children's Oncology Group (COG AHOD 0031) comparative analysis. TO Henderson, SK Parsons, K Wroblewski, L Chen, F Hong, S Smith, J McNeer, R Advani, R Gascoyne, LS Constine, S Horning, NL Bartlett, B Shah, JM Connors, J Leonard, BS Kahl, K Kelly, CL Schwartz, H Li, JW Friedberg, DL Friedman, LI Gordon, AM Evens. Cancer, in press. [\*COG AHOD 0031]

### Submitted Manuscripts

**S0016** Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort. L Rimsza, H Li, R Brazier, C Spier, D Persky, J Dunlap, M LeBlanc, N Barlett, JP Leonard, SM Smith, OW Press, JW Friedberg. Haematologica, pending revision/resubmission.



# Publication List by Committee

**S0016** Continued excellent outcomes in previously untreated follicular lymphoma patients after treatment with CHOP plus Rituximab or CHOP plus 131Iodine-Tositumomab - long term follow-up of Phase III randomized study SWOG-S0016. M Shadman, H Li, L Rimsza, JP Leonard, MS Kaminski, RM Brazier, CM Spier, AK Gopal, DG Maloney, B Cheson, S Dakhil, M LeBlanc, SM Smith, RI Fisher, JW Friedberg, OW Press. Journal of Clinical Oncology, resubmitted.

**S0410** Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent hodgkin lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). EP Smith, H Li, JW Friedberg, LS Constine, LM Rimsza, JR Cook, GG Laport, LL Popplewell, L A Holmberg, SM Smith, M LeBlanc, SJ Forman, RI Fisher, PJ Stiff. Biology of Blood and Marrow Transplantation, pending revision/resubmission.

**S0801** Phase 2 study of RCHOP, radioimmunotherapy and maintenance rituximab in untreated follicular lymphoma: SWOG S0801. PM Barr, H Li, WR Burack, M LeBlanc, SM Smith, AK Gopal, JD Floyd, DO Persky, OW Press, RI Fisher, JW Friedberg. Lancet Haematology, under review.

**S0806** A Phase I/II trial of vorinostat (SAHA) in combination with rituximab-chop in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. DO Persky, H Li, LM Rimsza, PM Barr, LL Popplewell, CL Bane, A Von Gehr, M LeBlanc, RI Fisher, SM Smith, JW Friedberg. American Journal of Hematology, submitted.

**C50604** Results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on interim FDG-PET for non-bulky stage I and II hodgkin lymphoma. DJ Straus, S-H Jung, B Pitcher, L Kostakoglu, JC Grecula, ED Hsi, H Schöder, LL Popplewell, JE Chang, CH Moskowitz, N Wagner-Johnson, JP Leonard, JW Friedberg, BS Kahl, BD Cheson, NL Bartlett. Journal of Clinical Oncology, submitted 9/5/17.

**CTSU 9177** Multicenter Phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. K Dunleavy, MA Fanale, JS Abramson, A Noy, P Fabrizio Caimi, S Pittaluga, S Parekh, A Lacasce, JW Hayslip, D Jagadeesh, S Nagpal, MJ Lechowicz, R Gaur, JW Leach, A Lucas, C Melani, M Roschewski, SM Steinberg, ES Jaffe, B Kahl, JW Friedberg, RF Little, NL Bartlett, WH Wilson. Blood, submitted.

## Melanoma Committee

### Published/Accepted Manuscripts

**E2607** A Phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral and vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607). K Kalinsky, S Lee, K Rubin, DP Lawrence, AJ Lafrarte, DR Borger, KA Margolin, MM Leitao, Jr, AA Tarhini, HB Koon, AL Pecora, AJ Jaslawski, GI Cohen, TM Kuzel, CD Lao, JM Kirkwood. Journal of Clinical Oncology Jul 15;123(14):2688-2697, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28334439>

**E4697** Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697). L Butterfield, F Zhao, S Lee, A Tarhini, K Margolin, R White, M Atkins, G Cohen, T Whiteside, J Kirkwood, D Lawson. Clinical Cancer Research Sep 1;23(17):5034-5043, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/28536308>

### Submitted Manuscripts

No publication information for this cycle.

## Other

### Submitted Manuscripts

**Multiple Studies** Frequency and description of drug interaction screening within SWOG Clinical Trials. DL Hertz, R Siden, J Modlin, L Au, LL Gabel, S-F Wong. American Journal of Health-System Pharmacy, under review.



### SWOG FACT

**SWOG Impact:** 14 new drugs, more than 100 changes to standard of care, more than 3 million years of life saved



Special thanks to our  
2017 Group Meeting Commercial Supporters\*

# We value their partnership.

## CME

### PLATINUM



CELGENE  
LILLY

### GOLD



ABBVIE  
NOVARTIS

### SILVER



ASTRAZENECA  
GENOMIC HEALTH  
MERCK

## Non-CME

### GOLD



TAKEDA ONCOLOGY

## Exhibitors

ABBVIE  
BOEHRINGER-INGELHEIM  
EXELIXIS  
GILEAD SCIENCES, INC.  
NOVARTIS  
OMNISEQ  
SEATTLE GENETICS  
TAIHO ONCOLOGY, INC.

Let's Make More Time

